Dysregulated Ca\textsuperscript{2+} Homeostasis as a Central Theme in Neurodegeneration: Lessons from Alzheimer’s Disease and Wolfram Syndrome

Manon Callens, Jens Loncke and Geert Bultynck *

KU Leuven, Laboratory of Molecular & Cellular Signaling, Department of Cellular & Molecular Medicine, Campus Gasthuisberg, O/N-I bus 802, Herestraat 49, BE-3000 Leuven, Belgium; manon.callens@kuleuven.be (M.C.); jens.loncke@kuleuven.be (J.L.)
* Correspondence: geert.bultynck@kuleuven.be

Abstract: Calcium ions (Ca\textsuperscript{2+}) operate as important messengers in the cell, indispensable for signaling the underlying numerous cellular processes in all of the cell types in the human body. In neurons, Ca\textsuperscript{2+} signaling is crucial for regulating synaptic transmission and for the processes of learning and memory formation. Hence, the dysregulation of intracellular Ca\textsuperscript{2+} homeostasis results in a broad range of disorders, including cancer and neurodegeneration. A major source for intracellular Ca\textsuperscript{2+} is the endoplasmic reticulum (ER), which has close contacts with other organelles, including mitochondria. In this review, we focus on the emerging role of Ca\textsuperscript{2+} signaling at the ER–mitochondrial interface in two different neurodegenerative diseases, namely Alzheimer’s disease and Wolfram syndrome. Both of these diseases share some common hallmarks in the early stages, including alterations in the ER and mitochondrial Ca\textsuperscript{2+} handling, mitochondrial dysfunction and increased Reactive oxygen species (ROS) production. This indicates that similar mechanisms may underly these two disease pathologies and suggests that both research topics might benefit from complementary research.

Keywords: calcium; mitochondria; mitochondria-associated ER membranes (MAMs); Alzheimer’s disease; Wolfram syndrome; neurodegeneration

Neurodegenerative diseases are characterized by the progressive degeneration or loss of neurons, a process that is causative of a wide array of symptoms. In this review, we discuss the important role of Ca\textsuperscript{2+} homeostasis in two neurodegenerative diseases: Alzheimer’s disease and Wolfram syndrome. The main focus lies on the ER and mitochondrial Ca\textsuperscript{2+} handling, as well as the close interaction between these organelles. By investigating the Ca\textsuperscript{2+} impairments, we show that these two very different diseases have more in common than first meets the eye.

1. Ca\textsuperscript{2+} Signaling

1.1. Ca\textsuperscript{2+} Signaling: A Brief Overview

Calcium ions (Ca\textsuperscript{2+}) are omnipresent in living cells and function as a versatile form of cellular communication, vital for the regulation of numerous cellular processes, including muscle contraction, fertilization, differentiation and metabolism [1,2]. For instance, several metabolic enzymes function with Ca\textsuperscript{2+} as a co-factor, including pyruvate-, isocitrate- and α-ketoglutarate dehydrogenase. In this way, a Ca\textsuperscript{2+} transfer from the endoplasmic reticulum (ER) to mitochondria can stimulate mitochondrial ATP production and survival [3]. A few examples of the involvement of Ca\textsuperscript{2+}-dependent processes in specific tissue/cell types are shown in Figure 1B–D. The living cells maintain a relatively low cytosolic Ca\textsuperscript{2+} concentration ([Ca\textsuperscript{2+}]\textsubscript{cyt}) (100 nM), compared to the [Ca\textsuperscript{2+}] inside the intracellular Ca\textsuperscript{2+}-storing
The rapid changes in the cytosolic [Ca\textsuperscript{2+}] can relay signals from either extracellular or intracellular stimuli to cellular effectors [4]. A critically controlled balance of the intracellular Ca\textsuperscript{2+} homeostasis is facilitated by the extensive ‘Ca\textsuperscript{2+} toolkit’ (Figure 1A). This toolkit comprises of several Ca\textsuperscript{2+} transporters and Ca\textsuperscript{2+}-binding proteins, thereby enabling the intracellular compartmentalization of Ca\textsuperscript{2+} and spatiotemporal organization of Ca\textsuperscript{2+} dynamics [2]. In the neurons, Ca\textsuperscript{2+} signaling plays a key role in synaptic transmission and plasticity, and the processes of learning and memory formation [5].

Figure 1. (A) Schematic representation of the Ca\textsuperscript{2+}-signaling toolkit. Ca\textsuperscript{2+} can enter the cell via store-operated, STIM-gated Orai channels, but also through voltage-gated Ca\textsuperscript{2+} channels (VOC), arachidonic acid-regulated Ca\textsuperscript{2+} channels (ARC), transient receptor potential channels (TRP) and ligand-gated ion channels (LGIC). The plasma membrane Ca\textsuperscript{2+} ATPase (PMCA) and the plasmalemmal Na\textsuperscript{+}/Ca\textsuperscript{2+} exchanger (NCX) are responsible for Ca\textsuperscript{2+} extrusion into the extracellular space. Ca\textsuperscript{2+} is mainly stored in intracellular Ca\textsuperscript{2+} stores, such as the endoplasmic reticulum, where it is buffered by calreticulin (CRT) and calnexin (CNX). Mobilization of Ca\textsuperscript{2+} from the ER into the cytosol occurs via two main channels, namely the inositol 1,4,5-trisphosphate receptor (IP\textsubscript{3}R) and the ryanodine receptor (RyR). Multiple ER-Ca\textsuperscript{2+} leak channels exist including presenilin (PSEN), Bak inhibitor-1 (BI-1), TRP melastatin 8 (TRPM8) and Sec61 translocon. ER Ca\textsuperscript{2+} depletion is detected by luminal ER Ca\textsuperscript{2+} sensors STIM1/STIM2, which subsequently activate plasmalemmal Orai to cause a Ca\textsuperscript{2+} influx across the plasma membrane. (Re)filling of the ER is mediated by the sarco-endoplasmic reticulum ATPase (SERCA). In the mitochondria, Ca\textsuperscript{2+} uptake is mediated by the voltage-gated anion channel (VDAC) on the outer mitochondrial membrane and the mitochondrial calcium uniporter (MCU) complex on the inner mitochondrial membrane. The main mitochondrial Ca\textsuperscript{2+} efflux transporter is the Na\textsuperscript{+}/Ca\textsuperscript{2+} exchanger (NCLX). Lysosomal Ca\textsuperscript{2+} release is mediated by transient receptor potential mucolipin (TRPML) and two-pore channel 2 (TPC2). This latter is regulated by nicotinic acid adenine dinucleotide phosphate (NAADP). Cytosolic Ca\textsuperscript{2+} is buffered by several Ca\textsuperscript{2+}-binding proteins including calmodulin (CaM), calbindin D-28 (CB-D28K), calretinin (CR) and parvalbumin (PV); (B–D): Schematic overview of relevant examples of functional correlates of Ca\textsuperscript{2+} signaling in specific tissue/cell types. CICR, Ca\textsuperscript{2+}-induced Ca\textsuperscript{2+} release; SR, sarcoplasmic reticulum; ER, endoplasmic reticulum; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NMDA, N-methyl-D-aspartate; LTP, long term potentiation; TRPM5, transient receptor potential cation channel subfamily M member 5.

The major intracellular Ca\textsuperscript{2+}-storage organelle is the ER, although the Golgi apparatus, the nuclear envelope and the lysosomes also serve as Ca\textsuperscript{2+} stores and contribute to the localized Ca\textsuperscript{2+} signaling. Moreover, the mitochondria can function as additional Ca\textsuperscript{2+} buffers upon sequestering elevations in the cytosolic Ca\textsuperscript{2+} [2]. The Ca\textsuperscript{2+} is mobilized from the ER into the cytosol, but also to the mitochondria, mainly via two different release...
channels: the inositol 1,4,5-trisphosphate (IP₃) receptor (IP₃R), which is the most ubiquitously expressed ER-resident Ca²⁺ release channel, and the ryanodine receptor (RyR) [6–8]. Both of the receptors consist of three different isoforms displaying distinct tissue-specific distribution patterns [7]. The IP₃Rs are opened upon binding of IP₃, a second messenger produced from phosphatidyl inositol 4,5-bisphosphate (PIP2), through the action of phospholipase C isoform, in response to the activation of G-protein-coupled receptors and tyrosine-kinase receptors by hormones, neurotransmitters, growth factors and/or antibodies [1]. In addition to this, the release of Ca²⁺ from the ER is enhanced by Ca²⁺ itself, in a process called Ca²⁺-induced Ca²⁺ release (CICR), which allows for the amplification of the cytosolic Ca²⁺ signals. Importantly, high cytosolic [Ca²⁺] can also inhibit ER Ca²⁺ release, illustrating the bell-curve shaped Ca²⁺ dependence of ER Ca²⁺ release [7]. Besides these intracellular Ca²⁺-release channels, a plethora of ER-resident proteins, including presenilins (PSENs), have been implicated in functioning as Ca²⁺-leak channels thereby mediating a constitutive passive Ca²⁺ leak from the ER Ca²⁺ stores [9–11]. For an extensive review of the ER-Ca²⁺ leak channels, we refer to [10]. In addition to this, the channels controlled by ER Ca²⁺ levels, such as TMCO1, have been identified [12]. The Ca²⁺-permeable TMCO1 channels are activated by high ER Ca²⁺ levels, thereby preventing ER Ca²⁺ overload. Conversely, the sarco-endoplasmic reticulum ATPase (SERCA) pump is responsible for the active maintenance or refilling of the internal Ca²⁺ stores [13]. Decreases in [Ca²⁺] in the ER cause a dissociation of Ca²⁺ from the Ca²⁺ sensors’ stromal interaction molecule (STIM1/STIM2) [14]. This results in the dimerization and redistribution of STIM proteins and the unfolding of their STIM1 Orai-activating region (SOAR) domains. The latter interact with the hexameric Orai1/2/3 channels, which are Ca²⁺-selective channels located on the plasma membrane enabling store-operated Ca²⁺ entry (SOCE) [14]. Recently, the helical M4x peptide of Orai was put forward as the target of interaction with the STIM SOAR domains, in which certain leucine residues in the M4x peptide were deemed to be critical for the interaction with SOAR [15]. The interaction of STIM with the Orai channels is aided by the STIM polybasic C terminus that binds acidic phospholipids at the plasma membrane, maintaining close contact between the ER and the plasma membrane. Consequently, the Orai channels are opened, thereby mediating store-operated Ca²⁺ influx from the extracellular environment into the cytosol and driving the SERCA-mediated refilling of the ER. Of note, the IP₃Rs functionally interact with the STIM/Orai complexes in such a way that the Ca²⁺ release is coupled to appropriate Ca²⁺ entry. The N-terminal STIM EF-hand motifs in the ER lumen are thought to inhibit IP₃R-mediated Ca²⁺ release [16]. Vice versa, the IP₃R-mediated decreases in the luminal [Ca²⁺] drive the clustering of STIM2 proteins and consequently augment the SOCE [16,17].

Besides the store-operated Ca²⁺ channels, other channels in the plasma membrane are responsible for Ca²⁺ entry, including the voltage-gated Ca²⁺ channels (VOC), receptor-operated Ca²⁺ channels (ROC), transient receptor potential (TRP) channels and arachidonic acid-regulated Ca²⁺ (ARC) channels [4]. On the other hand, the Ca²⁺ extrusion to the extracellular environment is mediated by the plasma membrane Ca²⁺ ATPase (PMCA) and the plasma membrane Na+/Ca²⁺ exchanger (NCX). The PMCA displays a higher Ca²⁺ affinity but lower capacity for Ca²⁺ transport, while the NCX shows the opposite properties [5,18].

The final aspect of the ‘Ca²⁺ toolkit’ consists of the Ca²⁺-binding proteins that are crucial for the regulation of Ca²⁺ concentration in the cytosol and in the intracellular stores. The fine regulation of Ca²⁺ dynamics by the Ca²⁺-binding proteins is not only exerted by Ca²⁺ buffering, but also through direct interaction with the target proteins (such as the IP₃R [19,20]) [21]. Examples of such Ca²⁺-binding proteins are calmodulin (CaM), which is able to bind four different Ca²⁺ ions, calbindin D-28 (CB-D28K), calretinin (CR) and parvalbumin (PV) [5,22]. Inside the ER, Ca²⁺ is buffered by calreticulin (CRT) and calnexin (CNX). More specifically for neurons, fourteen neuronal Ca²⁺ sensor proteins have been identified, such as hippocalcin, recoverin, neurocalcin-δ and GCAP1-3 [23]. These are important for the regulation of neuronal function and for the maintenance of neuronal health.
In addition, neuronal Ca\(^{2+}\)-binding proteins have been described that also directly interact with the IP\(_3\)R [24].

1.2. Mitochondrial Ca\(^{2+}\) Handling

Besides the ER, mitochondria also provide additional Ca\(^{2+}\)-buffering capacity and intervene in multiple Ca\(^{2+}\)-mediated signaling processes [25]. The Ca\(^{2+}\) uptake in the mitochondria is driven by the negative mitochondrial membrane potential (~180 mV) and is facilitated by the voltage-dependent anion channel (VDAC) on the outer mitochondrial membrane and the mitochondrial calcium uniporter (MCU) on the inner mitochondrial membrane. The Ca\(^{2+}\) is removed from the mitochondrial matrix via the Na\(^{+}\)/Ca\(^{2+}\) exchanger (NCLX), located on the inner mitochondrial membrane. The NCLX transports 3Na\(^{+}\) per Ca\(^{2+}\), but also displays Li\(^{+}\)-dependent Ca\(^{2+}\) transport [26]. The NCLX is regulated by kinase activity, mitochondrial membrane potential and proteases [26,27].

The ER is in close contact with the mitochondria, focalized at the mitochondria-associated ER membranes (MAMs) [28]. The MAMs are dynamic structures that allow ‘quasi-synaptic’ Ca\(^{2+}\) transfer from the ER to the mitochondria. The distance between the ER and the mitochondria at these MAMs varies from 10 nm to 30 nm [29,30].

In the MAMs, the IP\(_3\)Rs associate in a macromolecular complex with VDAC1 and GRP75 [31]. As such, the local elevations of [Ca\(^{2+}\)] in the microdomains, which can reach more than 10 µM Ca\(^{2+}\), can overcome the inherently low Ca\(^{2+}\) affinity of MCU, ensuring an adequate transfer of Ca\(^{2+}\) into the mitochondrial matrix, even under basal conditions [32]. Additionally, the translocase of the outer membrane 70 (TOM70) has been shown to bind to the IP\(_3\)R and to facilitate the IP\(_3\)-mediated Ca\(^{2+}\) transfer from the ER to the mitochondria [33]. Besides TOM70, other accessory proteins aid in MAM formation and stabilization, including the FUN14 domain-containing protein 1 (FUND1) and inositol-requiring enzyme 1 α (Ire1α) [34,35]. Although all of the IP\(_3\)R isoforms are found in the MAMs, IP\(_3\)R type 2 appears to be the most efficient at transferring Ca\(^{2+}\) from the ER to the mitochondria [36]. Importantly, the intracellular [Ca\(^{2+}\)] plays a dual role in regulating cell death [37]. Pro-survival Ca\(^{2+}\) oscillations promote the mitochondrial bio-energetics and the production of ATP by enhancing the activity of Ca\(^{2+}\)-dependent enzymes (pyruvate dehydrogenase, isocitrate dehydrogenase and α-ketoglutarate dehydrogenase) [3]. Instead, sustained Ca\(^{2+}\) elevations trigger cell death [28,38] involving a Ca\(^{2+}\)-dependent dissociation of cardiolipin from complex II, leading to excessive ROS production and the opening of the mitochondrial permeability transition pore (mPTP) [39,40].

The neurons have limited glycolytic capacity and therefore rely on proper mitochondrial ATP production for the maintenance of ionic gradients and for overall synaptic function [41]. The importance of MAM integrity in neurons is underpinned by the presence of the ER chaperone sigma-1 receptor (S1R) in the MAMs, where it stabilizes IP\(_3\)R and enhances the ER–mitochondrial Ca\(^{2+}\) transfer [42]. The S1R is implicated in neuroprotection and neuroplasticity and is bound to the luminal ER chaperone binding immunoglobulin protein (BiP). Under the conditions of [Ca\(^{2+}\)] ER depletion, S1R dissociates from BiP and loses its specific MAM localization [42].

Another example of a MAM protein regulating the ER–mitochondrial Ca\(^{2+}\) transfer is ER oxidoreductase 1-α (Ero1α), for which tightly regulated expression levels are necessary to ensure proper mitochondrial Ca\(^{2+}\) signaling. On the one hand, the knockdown of Ero1α inhibits ER–mitochondrial Ca\(^{2+}\) transfer by impacting both the IP\(_3\)-mediated Ca\(^{2+}\) release and mitochondrial Ca\(^{2+}\) uptake. On the other hand, the overexpression of Ero1α leads to elevated Ca\(^{2+}\) basal efflux through the IP\(_3\)R, lowering the steady state ER [Ca\(^{2+}\)] and reducing agonist-induced ER–mitochondrial Ca\(^{2+}\) transfer [43].

Besides regulating Ca\(^{2+}\), the MAMs are also involved in redox regulation by functioning as hosts for the sources and targets of reactive oxygen species (ROS) [44]. Interestingly, the Hajnóczky lab developed a novel strategy for measuring ROS at the MAMs by using drug-inducible synthetic linkers to target fluorescent H\(_2\)O\(_2\) sensors and ROS producers [44]. In doing so, they discovered dynamic H\(_2\)O\(_2\) nanodomains present at the MAMs that
are regulated by Ca²⁺ signaling. Moreover, it was shown that mitochondria generate oxidative bursts that are sensed by IP₃R, which in turn respond by generating Ca²⁺ signals [45,46]

1.3. Lysosomal Ca²⁺ Handling

Besides the plasma membrane and mitochondria, the ER is also in close contact with other cellular organelles, such as lysosomes. In fact, the lysosomes specifically buffer the cytosolic [Ca²⁺] elevations established by IP₃R-mediated Ca²⁺ release, but not the [Ca²⁺] elevations caused by other processes, such as SOCE [47]. Additionally, several Ca²⁺-release channels are embedded in the lysosomal membrane, i.e., transient receptor potential mucolipin (TRPML), two-pore channel 2 (TPC2) and P2X4 receptors [48]. At the ER–lysosomal contact sites, these lysosomal Ca²⁺ release channels may activate the ER Ca²⁺ release channels by CICR [49]. In the case of TPC2-mediated Ca²⁺ release, nicotinic acid adenine dinucleotide phosphate (NAADP) seems to be involved as a second messenger, by binding the Jupiter microtubule-associated homolog 2 (JPT2) and like-Sm protein 12 (LSM12), which were identified as interactors with TPC2 [50–52]. While TPC2 receptors function as Ca²⁺ permeable channels activated indirectly by NAADP, TPC2 receptors are directly activated by phosphatidylinositol 3,5 bisphosphate (PI(3,5)P2), activating TPC2 to selectively flux Na⁺ ions [53]. Additionally, the NAADP-producing enzymes, NADPH oxidase (NOX) 1 (NOX1)/NOX2 and dual NADPH oxidase (DUOX) 1 (DUOX1)/DUOX2, have been identified [54].

2. Alzheimer’s Disease

Over 55 million people worldwide live with dementia; a number that is rising on a daily basis due to aging of the global population [55]. Alzheimer’s disease (AD) accounts for around 60–70% of these cases and is therefore the most frequently occurring form of dementia. Patients with AD clinically present with behavioral changes, memory impairment, difficulties with communication and troubled reasoning and judgement [56]. The major neuropathological hallmarks of the disease include the irreversible loss of neurons, the formation of intracellular neurofibrillary tangles consisting of hyperphosphorylated tau protein and the accumulation of extracellular amyloid beta (Aβ) aggregates [57]. These Aβ peptides are formed by the subsequent proteolytic cleavage of the amyloid precursor protein (APP) by α-, β- and γ-secretases. The latter are mainly responsible for the generation of the Aβ peptides with a length of 42 amino acids (Aβ42), which are more prone to form aggregates and to accumulate in the brain than the more frequently observed Aβ40 [58,59]. An additional hallmark of AD is the chronic activation of microglial cells, resulting in increased neurotoxicity [60].

The more rare, familial form of AD (FAD) is characterized by an early-onset of the disease and is caused by autosomal dominant mutations in APP or in presenilins, the catalytic subunits of the γ-secretase complex. Though familial AD occurs less frequently than the sporadic, late-onset form of the disease, the pathological features of both forms are similar [61]. The major risk factors for the development of sporadic AD are age, gender—given that two-thirds of people with AD are female [55]—and carrying at least one apolipoprotein E (APOE) ε4 allele [62,63].

There is currently no disease-modifying therapy available for AD, as the only available treatment focuses on symptom relief. The current therapy consists of administration of three different acetylcholinesterase inhibitors (donepezil, rivastigmine and galantamine) and the NMDA receptor antagonist, memantine. Previous anti-amyloid strategies developed in the past few decades were limited in their success [64]. The more recently FDA-approved aducanumab bears more promise but awaits further confirmation of clinical benefit [65]. In addition, the neuroprotective properties of S1R have prompted several researchers to assess the potential of pharmacological S1R agonists (such as choline and PRE-084) in AD models. Choline ameliorated the amyloidogenic processing of APP and reduced the AD-related microglial activation in an AD mouse model [66]. PRE-084
reduced the Aβ levels in the brain and ameliorated the learning and memory deficits of mice injected with Aβ [67].

2.1. From Amyloid Hypothesis to Calcium Hypothesis

In 1992, Hardy and Higgins hypothesized that amyloid beta proteins were the causative agent in the pathology of AD [68]. To date, the Aβ hypothesis is the most widely accepted hypothesis and has served as the main guide for the development of therapeutic strategies. Although much evidence to support this hypothesis has been gathered over the past years [69], the hypothesis remains somewhat controversial [70]. One of the reasons to cast doubt upon the Aβ hypothesis is that the formation of Aβ plaques is also observed in cognitively well-functioning individuals and that the overall correlation between plaque deposition and cognitive function is rather weak [71–74]. Additionally, the failure of many anti-Aβ therapies suggest that amyloid plaque formation is not the only pathogenic factor involved in AD [64].

Only a few years later, Zaven S. Khachaturian proposed the Ca²⁺ hypothesis of AD [75]. This hypothesis is based on the similar pathological processes observed in AD and aging, such as increased oxidative and metabolic stress, decreased ATP production and overall Ca²⁺ dysregulation. In the following years, more and more evidence to support the Ca²⁺ hypothesis emerged and emphasized the important role of altered Ca²⁺ signaling in the pathophysiology of AD [76,77]. Moreover, targeting the dysregulation in Ca²⁺ homeostasis has been suggested as a potential approach for the treatment of AD [77,78]. The various downstream effects of dysregulated Ca²⁺ homeostasis include several molecular alterations underlying the AD pathogenesis, such as loss of synapses, mitochondrial dysfunction, oxidative stress and dysfunctional synaptic transmission and plasticity [79–81]. Of note, the alterations in Ca²⁺ handling are not exclusive for AD pathology, but have also been linked to other neurodegenerative diseases including Parkinson’s disease and Huntington’s disease [82].

Dreses-Werringloer et al. discovered a Ca²⁺-permeable channel named calcium homeostasis modulator 1 (CALHM1), directly linking Ca²⁺ homeostasis to AD and to the production of Aβ [83,84]. The CALHM1 is a transmembrane glycoprotein that generates a large Ca²⁺ conductance across the plasma membrane. The CALHM1 plays a role in neuronal excitability and shares similar properties with connexins, pannexins and innexins [85,86]. It was shown that a single nucleotide polymorphism in the CALHM1, resulting in proline substitution to leucin at codon 86, was associated with different AD cases. Moreover, this mutation was reported to cause an impairment of the plasma membrane Ca²⁺ permeability, a reduction in the cytosolic Ca²⁺ rise after removing extracellular Ca²⁺ and to affect APP processing [83].

Multiple studies indicate an increase in the resting cytosolic [Ca²⁺] in AD. Kuchibhotla et al. reported a Ca²⁺ overload in individual neurites and spines in mice, which was dependent on the proximity to Aβ deposits [87]. Moreover, Aβ plaque deposition was required to induce Ca²⁺ overload. The magnitude of the Ca²⁺ overload was similar to levels that are associated with long-term depression, an important neuronal process characterized by decreased synaptic strength that is also affected in AD. Similarly, resting cytosolic [Ca²⁺] was significantly increased in the cultured, cortical neurons from a triple transgenic AD mouse model (3xTg-AD). However, in the absence of extracellular Ca²⁺, the intracellular Ca²⁺ levels almost completely returned to normal, suggesting that an influx of extracellular Ca²⁺ plays a role in the observed intracellular Ca²⁺ overload. It was further demonstrated that increases in Ca²⁺ influx via L-type Ca²⁺ channels and increased IP₃R-mediated Ca²⁺ release are responsible for the elevated cytosolic Ca²⁺ levels. The observed disturbances in the Ca²⁺ signaling occur prior to the onset of plaque formation and neurofibrillary tangles, indicating the crucial role of Ca²⁺ signaling in the early pathophysiology of AD [88].
2.2. Changes in ER Ca\textsuperscript{2+} Handling in AD

The Ca\textsuperscript{2+} hypothesis was further supported by the discovery of various FAD-linked mutations in PSEN causing alterations in intracellular Ca\textsuperscript{2+} release (Figure 2) [11,89,90]. Two possible mechanisms for this have been proposed. On the one hand, it is suggested that PSENs act as ER Ca\textsuperscript{2+} leak channels, independent of their function as a catalytic subunit of the γ-secretase complex, and that this leak function is abolished due to PSEN mutations [11]. Additionally, the ER Ca\textsuperscript{2+} overload observed in the cells expressing PSEN mutants, leads to increased Ca\textsuperscript{2+} release after IP\textsubscript{3}R activation. Interestingly, the PSENs undergo endoproteolytic cleaving in order to be stable and functional in the γ-secretase complex, but the authors suggest that the holoprotein of PSENs is responsible for the ER Ca\textsuperscript{2+} leak function. Indeed, the PSEN1 ΔE9 mutant, a mutant that is unable to undergo endoproteolytic cleavage, showed higher ER Ca\textsuperscript{2+}-leak channel activity than WT PSEN1 [11]. Additionally, the phosphorylation of PSEN1 appeared critical for its ER Ca\textsuperscript{2+}-leak function [10,91]. On the other hand, single channel analyses showed that different PSEN1 mutations directly sensitize IP\textsubscript{3}R activity, thereby resulting in hyperactive Ca\textsuperscript{2+} signaling in four different cell systems [90]. This gain-of-function effect of FAD-linked PSEN mutations was also independent of the γ-secretase activity of PSEN. More specifically, the PSEN mutations drive the IP\textsubscript{3}R into the H mode, the gating mode with high open probability and bursting channel behavior [92], causing a sufficiently large Ca\textsuperscript{2+} flux to enable signal amplification by CICR [90]. In agreement, Stutzmann et al. showed increased IP\textsubscript{3}-evoked Ca\textsuperscript{2+} responses in neurons expressing PSEN1 mutants by using whole-cell patch-clamp recording, flash photolysis of the caged IP\textsubscript{3} and two-photon imaging in brain slices [93]. In addition, administration of oligomeric A\textsubscript{β}42 was observed to raise cytosolic [Ca\textsuperscript{2+}] through an ER Ca\textsuperscript{2+} release, in part via an IP\textsubscript{3}R-mediated Ca\textsuperscript{2+} release, but also through an IP\textsubscript{3}R-independent Ca\textsuperscript{2+} leak from the ER [94].

![Figure 2. Schematic overview of changes in ER Ca\textsuperscript{2+} handling occurring in Alzheimer's disease. Mutations in presenilin (PSEN) were shown to increase the expression of the RyR and to cause an enhancement of IP\textsubscript{3}R-mediated Ca\textsuperscript{2+} release. Additionally, the RyR is responsible for some of the IP\textsubscript{3}R-mediated Ca\textsuperscript{2+} release through CICR. PSENs were also reported to form ER Ca\textsuperscript{2+} leak channels, a function that is abolished by PSEN mutations and which causes ER Ca\textsuperscript{2+} overload. PSEN mutations also display an inhibitory effect on store-operated Ca\textsuperscript{2+} entry, which may be involved in the generation of toxic A\textsubscript{β} deposits. Finally, PSENs interact with SERCA which also impacts the A\textsubscript{β} formation.](image-url)
Besides the IP₃R, changes in the RyR activity have also been linked to AD (Figure 2). Chan et al. demonstrated an increased expression of the RyR3 in cultured neurons harboring PSEN1 mutations. Consequently, Ca²⁺ release following pharmacological stimulation of RyR was enhanced in comparison to WT PSEN1 [95]. Similar results were obtained in the 3xTg mouse model of AD [96]. From co-immunoprecipitation studies, a direct interaction between PSEN1 and RyR was suggested. However, it has not yet been determined how the PSEN mutants would affect interaction with RyR [95]. With the use of radiolabeled ryanodine, an increase in the RyR expression in the subiculum and in the CA1 and CA2 regions of the hippocampus was demonstrated in the very early stages of pathology. In contrast, a reduced binding of radiolabeled ryanodine, and thus RyR loss, was observed in the later stages of the disease in all of the hippocampal regions that are affected by neurofibrillary pathology in AD [97]. Additionally, it was demonstrated that the IP₃-evoked Ca²⁺ release occurs in the greater majority of the AD mice mediated through the RyR, which is not the case in the WT mice. This is probably due to CICR initiated by large Ca²⁺ releases through upregulated RyRs [98]. Importantly, the ER Ca²⁺ signaling, and, more specifically, the RyR-mediated Ca²⁺ release, plays a role in synaptic transmission. The enhanced RyR-mediated Ca²⁺ signals that are observed in the 3xTg-AD mice can therefore have a modulatory effect on the synaptic activity that are not present in the control mice. Moreover, the RyR-mediated Ca²⁺ release impacts both presynaptic and postsynaptic events in the 3xTg-AD mice, but plays a much smaller role in the control mice [99].

The neurons derived from transgenic mice expressing mutant PSEN1 also displayed a decrease in SOCE, which is independent of the expression of APP and independent of the γ-secretase activity of PSEN1 [100]. Additionally, Yoo et al. indicated that treating cells with a SOCE inhibitor selectively increased the generation of Aβ42 peptides, suggesting that impairments in SOCE may be an early event in AD pathology [101]. On the other hand, an enhancement in the ER [Ca²⁺] was observed which did require APP expression [100]. Similar elevated ER Ca²⁺ levels were found in the fibroblasts carrying a FAD-linked PSEN1 mutation. It is suggested that this elevation in the ER Ca²⁺ levels is responsible for the attenuation of SOCE, since reaching low Ca²⁺ levels below the threshold to activate SOCE is prevented [102]. The exact mechanism by which the PSEN1 mutations cause this increase in intracellular Ca²⁺-store filling is not yet elucidated. However, previous research indicated an increased expression of acylphosphatase, an enzyme enhancing the activity of SERCA and thus supporting ER-store filling, in the fibroblasts of patients with AD [102,103].

Green et al. further demonstrated that the PSENs play a role in ER store filling via SERCA, as it was reported that the PSENs are necessary for properly maintaining SERCA activity [104]. Moreover, the PSENs were shown to colocalize and physically interact with SERCA. The knockdown of SERCA gave rise to a phenotype resembling presenilin-null cells, characterized by increased basal cytosolic Ca²⁺ levels, which could be rescued by overexpressing PSEN. Additionally, SERCA was demonstrated to impact on the Aβ production with the inhibition of SERCA activity rapidly reducing the production of Aβ40 and Aβ42 proteins [104].

To conclude, an important role of Ca²⁺ signaling in early AD is emerging. A vicious feed forward cycle appears to exist between Ca²⁺-signaling dysregulation and APP processing [105] (Figure 3). On the one hand, aberrant Ca²⁺ signals have an effect on APP processing [106] although studies researching this topic are rather sparse. On the other hand, administration of oligomeric Aβ was shown to increase cytosolic [Ca²⁺] [94], thereby further driving the formation of Aβ.
Figure 3. Schematic overview of the feed forward interplay between Ca\textsuperscript{2+} signaling and Aβ. Mutations in presenilin (PSEN) cause dysregulations in Ca\textsuperscript{2+} homeostasis, which then causes altered processing of APP and the formation of Aβ. In turn, this further impacts Ca\textsuperscript{2+} homeostasis.

2.3. Mitochondrial Ca\textsuperscript{2+} Dysregulation in AD

It has become more and more clear that mitochondria play a fundamental role in the pathophysiology of AD (Figure 4) [107]. More specifically, mitochondrial dysfunction has been reported as an early event in AD, as it precedes the onset of plaque formation in the 3xTg-AD mouse model [108]. Yao et al. demonstrated decreased mitochondrial bioenergetics, increased oxidative stress and increased mitochondrial amyloid load in the 3xTg-AD mouse model [108]. Other studies confirm the impairment in mitochondrial function in the brains of AD mouse models or AD patients [109–111].

Figure 4. Representation of the mitochondrial changes reported in Alzheimer’s disease. Aβ has been shown to induce mitochondrial Ca\textsuperscript{2+} overload via different mechanisms. For instance, Aβ inhibits Ca\textsuperscript{2+} extrusion by blocking the Na\textsuperscript{+}/Ca\textsuperscript{2+} exchanger (NCLX). On the other hand, Aβ promotes Ca\textsuperscript{2+} uptake via interaction with mitochondrial Ca\textsuperscript{2+} uniporter (MCU). Aβ deposits are also detected inside the mitochondria where they further contribute to dysregulated Ca\textsuperscript{2+} homeostasis. The uptake of Aβ in the mitochondria is reportedly regulated by translocase of the outer membrane (TOM).
The mitochondrial Ca\textsuperscript{2+} overload causes increased production of ROS and further leads to mitochondrial dysfunction.

The mitochondrial dysfunction observed in AD is clearly linked to the occurrence of A\textbeta deposits as A\textbeta has been detected in the mitochondria of AD mouse models and post-mortem brains of AD patients \cite{112}. It is suggested to be imported in the mitochondrial matrix via the translocase of the outer mitochondrial membrane (TOM) machinery \cite{113}, and the accumulated A\textbeta directly impairs the mitochondrial Ca\textsuperscript{2+} homeostasis. Mitochondrial Ca\textsuperscript{2+} overload was detected in an AD mouse model, but only after the appearance of A\textbeta in the brains of the mice, suggesting the importance of A\textbeta deposits as the initial trigger for this mitochondrial Ca\textsuperscript{2+} overload. Moreover, Calvo-Rodriguez et al. demonstrated that the application of soluble A\textbeta oligomers to the brain of naïve mice caused an increased mitochondrial Ca\textsuperscript{2+} uptake and elicited subsequent mitochondrial Ca\textsuperscript{2+} overload \cite{114}. Mitochondrial Ca\textsuperscript{2+} overload consequently results in severe oxidative damage, loss of mitochondrial membrane integrity, deprivation of ATP production and eventually cell death \cite{115}.

The exact mechanism by which A\textbeta deposits provoke mitochondrial Ca\textsuperscript{2+} uptake has not been established. It has been suggested that A\textbeta forms Ca\textsuperscript{2+}-permeable channels in bilayer membranes \cite{116}, or that it causes the formation of non-specific ion channels in the plasma membrane and the membranes of intracellular organelles \cite{117}. Alternatively, increased Ca\textsuperscript{2+} uptake via the MCU complex is thought to play a role \cite{118}. The selective blocking of the MCU complex abolished the mitochondrial Ca\textsuperscript{2+} overload caused by soluble A\textbeta application, indicating the potential of the MCU complex as a therapeutic target \cite{114,119}. Another proposed mechanism for the mitochondrial Ca\textsuperscript{2+} overload is via the impaired Ca\textsuperscript{2+} efflux through the Na\textsuperscript{+}/Ca\textsuperscript{2+} exchanger (NCLX), the main mitochondrial Ca\textsuperscript{2+} efflux transporter. The brain samples from AD patients showed a reduced expression and functionality of the NCLX, causing an increase in the mitochondrial Ca\textsuperscript{2+} concentration \cite{120,121}. The genetic rescue of NCLX expression in 3xTg-AD mice abolished the cognitive decline and reduced neuronal pathology. Moreover, the mitochondrial Ca\textsuperscript{2+} efflux via the NCLX is also inhibited by tau, thereby linking the other major pathophysiological hallmark of AD to impaired mitochondrial Ca\textsuperscript{2+} handling \cite{122}.

A direct molecular link between A\textbeta and mitochondrial dysfunction is established by A\textbeta-binding alcohol dehydrogenase (ABAD), a member of the short-chain dehydrogenase-reductase family that is enriched in the mitochondria of neurons. The ABAD-protein levels were reported to be elevated in the affected regions of the AD brain \cite{123}. Moreover, ABAD and A\textbeta form a highly specific complex that is detected in the brains of AD patients and in the mitochondria of a transgenic AD mouse model \cite{124}. Similarly, Yao et al. described a correlation between the increase in mitochondrial A\textbeta and the rise in ABAD levels in the brains of 3xTg AD mice \cite{108}. The ABAD-A\textbeta complexes elicit cellular dysfunction by causing ROS leakage, mitochondrial dysfunction, increased opening of the mitochondrial membrane permeability transition pore (MPT) and eventually cell death \cite{123}.

2.4. MAMs and AD

MAM homeostasis is key for cellular health \cite{28} and is well-established to be affected in neurodegenerative diseases, including AD. Moreover, altered MAM function is even suggested as a main pathogenic cause in AD \cite{125}. The evidence to support the role of MAMs in AD pathophysiology comes from the observation that APP, PSENS and the complete γ-secretase complex predominantly reside in the MAMs \cite{126}. Additionally, the ER-mitochondrial communication and MAM function is increased in AD patient fibroblasts and in AD animal models \cite{127}. Fernandes et al. reported that cells overexpressing the Swedish mutation in APP cause an accumulation of APP in MAMs and mitochondria and affect the ER-mitochondria contacts, ER-mitochondria Ca\textsuperscript{2+} transfer and mitochondrial function and dynamics \cite{125}. Moreover, the exposure of hippocampal neurons to A\textbeta deposits triggered an increase in the number of the ER-mitochondrial contact sites and
enhanced the expression of different MAM-associated proteins, including IP3R3 and VDAC1. Similarly, an upregulation of MAM-associated proteins was also detected in the APPswe/Lon mouse model, which overexpresses the Swedish (K670N/M671L) and London (V717I) mutations in APP [128].

Alternatively, C99, a product derived from APP cleavage by \( \beta \)-secretase, accumulates at the MAMs and causes disturbances in the sphingolipid homeostasis and overall alterations in the lipid composition of the MAMs. Therefore, this MAM-localized C99 accumulation has been reported as a driver of the mitochondrial dysfunction in AD [129]. Moreover, C99 accumulation triggers mitochondrial dysfunction independent of A\( \beta \) in both in vitro and in vivo models of AD [130]. In agreement, Lauritzen et al. found that C99 accumulated at early stages in the 3xTg AD mice, months before the A\( \beta \) deposits are detected. This accumulation is particularly present in AD-sensitive brain regions, such as the hippocampus [131].

3. Wolfram Syndrome

3.1. Introducing Wolfram Syndrome

Wolfram syndrome (WS) is a rare, genetic neurodegenerative disease first described by Wolfram and Wagner in 1938 [132]. The main pathological hallmarks of WS include optic nerve atrophy, diabetes insipidus, diabetes mellitus and hearing loss [133]. Additionally, WS patients often present with different neurological conditions, such as ataxia, brain stem atrophy, autonomic and peripheral neuropathy, headaches and seizures [134]. The treatment is mainly limited to ameliorating the emerging symptoms and patients usually die around the age of 30, often due to respiratory failure caused by brain stem atrophy [135].

Two different types of WS exist, namely WS type 1 (WS1), accounting for over 90% of the cases, and WS type 2 (WS2). The pathophysiology of WS1 and WS2 slightly differs, as diabetes insipidus is solely observed in the WS1 patients, while upper intestinal ulcers and defective platelet aggregation are mainly present in patients with WS2 [136,137]. Patients with WS1 carry a loss-of-function mutation in the WFS1 gene encoding for wolframin (Wfs1), a transmembrane protein located at the ER. The Wfs1 is highly expressed in brain tissue, pancreatic \( \beta \)-cells and in the heart [138–140]. Mutations in WFS1 cause elevations in ER stress, alterations in pancreatic \( \beta \)-cells and cause stress-induced apoptosis [141]. Moreover, wolframin has been shown to play a role in maintaining ER homeostasis and in the unfolded protein response (UPR) [142–144].

CISD2 is the second causative gene for WS, encoding a 15 kDa redox active protein named Cisd2, though known under various aliases, such as Miner1, Naf-1, ERIS, WS2 and CDGSH2 [145]. Cisd2 is an ER-localized protein, but is enriched in the MAMs [146]. The physiological roles of Cisd2 are not completely elucidated, but Cisd2 is thought to be involved in mitochondrial iron transport [147]. Through the CDGSH domain, Cisd2 can bind to iron–sulfur clusters, which can be donated by Cisd1, a close family member of Cisd2 [148]. In this way, Cisd1-Cisd2 might partake in a relay system responsible for shunting iron outside of the mitochondria [147]. Moreover, Cisd2 is generally viewed as a prolongevity factor and therefore plays a role in aging and various cancers. Most cell types ubiquitously express Cisd2, underscoring its vital role in maintaining cellular homeostasis [149]. For instance, the overexpression of Cisd2 in an APP/PS1 transgenic mouse model for AD resulted in a neuroprotective effect, probably by preventing mitochondrial damage [150]. Conversely, a lack of Cisd2 can lead to chronic injury, such as that seen in the cornea of patients with epithelial disease [151]. A vicious cycle of aberrant wound healing, hindered by Ca\(^{2+}\) dyshomeostasis and mitochondrial dysfunction, leads to the hyperproliferation and exhaustion of the corneal epithelial stem cells [151,152].
3.2. The Role of Ca\textsuperscript{2+} in WS

A unifying principle for the two distinct WS-associated proteins, Wfs1 and Cisd2, is their involvement in Ca\textsuperscript{2+} homeostasis (Figure 5) [145]. An early electrophysiological study of Xenopus oocytes already pointed towards an interplay between the Wfs1 and IP\textsubscript{3}Rs. The channel activity recordings in the lipid bilayers uncovered an elevated IP\textsubscript{3}-induced current when Wfs1 is reconstituted into the bilayers [153]. Of note, the authors hypothesized that Wfs1 can function as a Ca\textsuperscript{2+}-permeable channel [153], though no further studies validated this. Conversely, the Wfs1-deficient neurons displayed decreased IP\textsubscript{3R}-mediated Ca\textsuperscript{2+} release and perturbed mitochondrial dynamics, leading to delayed development [154]. Further evidence for a stimulatory role for Wfs1 on IP\textsubscript{3R}-mediated Ca\textsuperscript{2+} release stems from a study of WS1 patient fibroblasts, which showed that Wfs1 is important for the Neuronal Ca\textsuperscript{2+} Sensor 1 (NCS1) stability and binding to IP\textsubscript{3R} in the MAMs. Since NCS1 can sensitize IP\textsubscript{3R} to IP\textsubscript{3}, the Wfs1 stimulates the ER–mitochondrial Ca\textsuperscript{2+} transfer [155]. A second member of the Ca\textsuperscript{2+} toolkit interacting with Wfs1 is the SERCA pump. The Wfs1 was reported to bind and regulate SERCA abundance by mediating its proteasomal degradation [156].

The exact impact of Wfs1 on cellular Ca\textsuperscript{2+} homeostasis is still not entirely clear, but most studies seem to point towards a higher resting cytosolic [Ca\textsuperscript{2+}] upon Wfs1 deficiency, possibly through an increased Ca\textsuperscript{2+} leak from the ER through the Ca\textsuperscript{2+}-release channels [154,157,158]. Additionally, the reduced ER Ca\textsuperscript{2+} uptake could explain the elevated cytosolic Ca\textsuperscript{2+} levels, since in the Wfs1-deficient cells, the ER Ca\textsuperscript{2+} store content and store refilling is decreased [159]. These elevated cytosolic Ca\textsuperscript{2+} levels are thought to hyperactivate calpain 2, a Ca\textsuperscript{2+}-dependent pro-apoptotic protease. In vitro therapeutic interventions with dantrolene, an RyR inhibitor, normalized the resting cytosolic [Ca\textsuperscript{2+}] and prevented excessive calpain 2-mediated cell death in the Wfs1-deficient cells [157]. Similarly, the calpain inhibitor XI and ibudilast, a known interactor with NCS1, ameliorated the resting cytosolic [Ca\textsuperscript{2+}] and excessive cell death in the Wfs1-deficient cells [158]. Currently, the administration of dantrolene to WS patients is being investigated in a clinical trial. Generally, dantrolene seems to be well-tolerated by WS patients; however, the efficacy of dantrolene as a disease-delaying or -reverting compound is still unknown and awaits confirmation.
in a trial with a larger sample size. In pediatric patients, a modest increase in β cell function could be observed, which might indicate a certain level of remaining β cells is necessary for dantrolene efficacy [160].

Similar to Wfs1, a deficiency in Cisd2 leads to elevated cytosolic Ca\(^{2+}\) levels [146,161–164]. Cisd2 also interacts with IP\(_3\)R as well as B-cell lymphoma 2 (Bcl-2), a known modulator of IP\(_3\)R [165,166]. This raises the possibility that Cisd2 can indirectly regulate IP\(_3\)R activity through Bcl-2 [145]. In fact, biophysical studies have established that the Cisd2-Bcl-2 complex relies on the interaction between the catalytic domain of Cisd2 with the BH4 domain of Bcl-2 [167], the very same domain that is responsible for IP\(_3\)R inhibition [168,169]. Alternatively, CISD2 might directly modulate IP\(_3\)R activity, irrespective of Bcl-2 [145]. The IP\(_3\)R activity is strongly impacted by oxidation [46,170] including at the ER–mitochondrial contact sites, where the ROS boost the IP\(_3\)-mediated Ca\(^{2+}\) fluxes [45]. As Cisd2 seems to function as a cellular antioxidant, cells lacking Cisd2 might be prone to increased IP\(_3\)R oxidation [149,171].

An additional mode of action of Cisd2 in the regulation of cytosolic [Ca\(^{2+}\)] could occur via modulating SERCA activity. Indeed, findings from murine Cisd2 KO fibroblasts [172], hepatocytes from heterozygous Cisd2 KO mice [173] and cardiomyocytes from Cisd2 KO mice [162] suggest that ER [Ca\(^{2+}\)] is decreased when lacking Cisd2. Additionally, Cisd2 interacted with SERCA2b [173] and SERCA2a [162]. On the contrary, in WS2 patients’ lymphoblastoids [174] and Cisd2 KO murine myoblasts [164], the ER [Ca\(^{2+}\)] was increased, while the findings in other cell types reported unchanged ER [Ca\(^{2+}\)] upon loss of Cisd2 [164,165]. Although it is clear that Cisd2 impacts on the Ca\(^{2+}\) homeostasis, much remains to be discovered on how Cisd2 interacts with the different actors in the Ca\(^{2+}\) toolkit.

### 3.3. Mitochondrial Dysfunction in WS

Although WS was initially considered to be a mitochondriopathy, the research focus has shifted towards ER dysfunction and ER–mitochondrial crosstalk, due to the presence of both the Wfs1 and Cisd2 in the MAMs [133]. For instance, the Wfs1 was shown to partake in a macromolecular complex in the MAMs involving IP\(_3\)R and NCS1. The Wfs1-deficient cells exhibited reduced ER–mitochondrial contact and ER–mitochondrial Ca\(^{2+}\) transfer, ultimately resulting in impaired mitochondrial function [155,158]. At the MAMs, Wfs1 interacts with S1R, which similarly to NCS1 can also positively modulate ER–mitochondrial Ca\(^{2+}\) transfer. Stimulation of S1R with PRE-084, a S1R agonist, could overcome the Wfs1-deficiency-mediated decrease in IP\(_3\)R-mediated Ca\(^{2+}\) release and ER–mitochondrial Ca\(^{2+}\) transfer [175]. The PRE-084, could also alleviate mitochondrial abnormalities associated with reduced MAM functionality, such as increased mitophagy [175]. Additionally, WS1 is linked with impaired mitochondrial dynamics, as knocking down the Wfs1 in neurons decreased the mitochondrial mass, mobility and fusion, while increasing the rate of mitophagy [154].

Similarly, Cisd2 was established to be a MAM-resident protein. In the MAMs, Cisd2 can interact with the protein GTPase IMAP family member 5, which is vital for the differentiation process of adipocytes [146]. Moreover, a study of the WS2 patients’ fibroblasts found an increase in the ER–mitochondrial Ca\(^{2+}\) transfer and closer ER–mitochondrial contact, leading to mitochondrial hyperfusion [146]. Furthermore, the absence of Cisd2 leads to impaired biogenesis [146], aberrant mitochondrial metabolism [176], increases in mitochondrial ROS [177] and iron levels [178,179] and mitochondrial swelling [164].

Of note, the deficiencies in both Wfs1 or Cisd2 are associated with ER stress [139,142,172,180,181], a process which by itself is known to lead to mitochondrial dysfunction [182].

### 4. Similarities between AD and WS

AD and WS are both neurodegenerative disorders that display very different clinical manifestations. However, some similarities can be found between these two distinct diseases. A first resemblance between AD and WS is that no disease-modifying treatment is
available, and the only available therapy is focused on ameliorating the symptoms. This points out the difficulties of generating therapeutic strategies in neurodegeneration and already shows that much more research is needed in the field.

Mechanistically, some other similarities can be observed, mainly in the early pathology of the diseases. A first link between the two diseases involves tau. The hyperphosphorylated tau forming neurofibrillary tangles is a major hallmark of AD and is serving as a potential therapeutic target [183]. Recently, Chen et al. described a novel function for Wfs1 in the development and progression of tau pathology [184]. The Wfs1 can interact with tau protein and affect its aggregation and propagation. Moreover, increased Wfs1 reduced tau pathology and neurodegeneration in PS19 mice, a widely used tauopathy model which resembles AD-like pathology. On the other hand, Wfs1 deficiency increased the pathological tau and apoptosis, and impaired the spatial learning and memory in PS19 mice [184].

Most of the similarities between AD and WS are related to Ca²⁺ homeostasis and mitochondrial function, indicating the pivotal role of (mitochondrial) Ca²⁺ signaling in the early stages of neurodegenerative disorders. The Ca²⁺ homeostasis plays a key role in AD, as indicated by the Ca²⁺ hypothesis of AD pathology [75,79], as well as in WS, where it is the unifying factor between Wfs1 and Cisd2 [145]. A common observation in both of the diseases is an increase in cytosolic [Ca²⁺] [87,90,93,154,157,158]. Different mechanisms for this have been proposed, but in both AD and WS, there is a link with the ER store filling via SERCA. The PSENs in AD and Wfs1 and Cisd2 in WS have been shown to interact with SERCA [102–104,156,162]. The Ca²⁺ overfilling of the ER can lead to exaggerated IP₃R-mediated Ca²⁺ releases and thus contributes to elevated cytosolic [Ca²⁺]. Moreover, a direct link with the IP₃R is established in both of the disorders. The mutations in PSEN have been shown to augment the activity of the IP₃R [90], and both Wfs1 and Cisd2 display a direct and indirect interaction with the IP₃R [145,149,154,155,171]. Additionally, hyperactive RyR-mediated Ca²⁺ release is linked with both WS and AD [157,185,186]. In the case of WS, the administration of dantrolene, an RyR inhibitor, can rescue this defect in vitro and its efficacy in vivo is currently being investigated in clinical trials [157,160]. Therefore, the use of dantrolene, either alone or in combination with immunotherapy, might also be considered for the treatment of AD. Additionally, post-translation modification of the RyR2 or RyR2 mutations have been linked to AD [186,187]. More specifically, Yao et al. reported that mice carrying the RyR2-R4496C mutation, which increases the open probability of the channel, displayed neuronal hyperactivity and impaired learning and memory formation. Similarly, increasing the open probability of RyR2 in 5xFAD mice exacerbated the onset of these symptoms [187]. Hence, it would be interesting to assess whether patients with RyR2 mutations or other channelopathies are at risk of not only developing AD but also exhibiting features that resemble WS. However, such RyR2 mutations have not yet been reported in WS patients.

The resemblances between AD and WS are not limited to the ER, but are also observed at mitochondrial level. The mitochondrial Ca²⁺ overload has been reported, as well as an increased ER–mitochondrial Ca²⁺ transfer in WS2 patients’ fibroblasts [146]. Similarly, the ER–mitochondrial Ca²⁺ transfer is affected in cells carrying mutations in APP [125]. In both AD and WS, this leads to mitochondrial dysfunction and increases in ROS production [108–111,155–158,177].

Another very interesting link between AD and WS is through S1R. S1R resides at MAMs where it acts on IP₃Rs and regulates the Ca²⁺ signaling and survival [42]. The WFS1 was reported to interact with the S1R and therefore to positively modulate the ER–mitochondrial Ca²⁺ transfer [175]. Stimulation with a S1R agonist could counteract the impaired Ca²⁺ homeostasis and mitochondrial deficits observed in WS [175]. However, also in AD, S1R is emerging as a novel target. The S1R is downregulated in AD and other neurodegenerative diseases, although the exact mechanism for this downregulation is not understood [188–190]. The treatment of primary hippocampal cultures obtained from WT mice with an S1R agonist protected against the Aβ oligomer toxicity in mushroom spines...
Moreover, the S1R agonist also prevented mushroom spine loss in AD-causing mutations in hippocampal neuronal cultures [191]. Therefore, S1R stimulation might be an exciting strategy in both AD and WS, and in neurodegeneration in general, to target early defects found in the disease pathology.

Alternatively, the antiapoptotic protein Bcl-2 can also be linked to both diseases. Multiple members of the Bcl-2 family have been associated with AD, but mainly a downregulation of Bcl-2 itself has been linked to AD [192]. Moreover, Bcl-2 is suggested as a potential therapeutic target for AD since the overexpression of Bcl-2 in a transgenic AD mouse model suppressed the formation of plaques and neurofibrillary tangles and improved memory retention [193]. On the other hand, Cisd2 has been shown to directly interact with Bcl-2, and is important for Bcl-2’s function in inhibiting Beclin-1-mediated autophagy [165,166].

Finally, Liangping et al. reviewed the role of Wfs1 and Cisd2 in AD, providing a direct link between WS and AD [194]. For instance, Cisd2 overexpression was shown to promote survival and protect against neuronal loss in an AD mouse model, while Cisd2 deficiency accelerates AD pathology [150]. Therefore, Cisd2-based therapies could be exploited as potential therapeutic strategy in AD. Remarkably, Cisd2 also protects against mitochondrial damage and thus the protective effect to neuronal loss could also be mediated though the regulation of mitochondrial function [150].

In summary, WS and AD entail common hallmarks in early disease pathology that can be exploited as potential treatment strategies to target both diseases. The possibilities for such therapeutic targets include S1R, SERCA, RyR and the IP3R to normalize increased cytosolic [Ca2+], or Wfs1- and Cisd2-based therapies (Figure 6). It would be very beneficial to further investigate these similar targets so that potential drugs for AD can also be effective for WS, and vice versa.

Figure 6. Schematic overview indicating potential therapeutic strategies to target both Alzheimer’s disease and Wolfram syndrome. Possible therapeutic targets are indicated by a red asterisk. S1R, sigma 1 receptor; Bcl-2, B-cell lymphoma 2; IP3R, inositol trisphosphate receptor; RyR, ryanodine receptor; SERCA, sarco/endoplasmic reticulum ATPase; VDAC, voltage-dependent anion channel; Wfs1, wolframin.

5. Conclusions

AD and WS are both neurodegenerative diseases that display distinct hallmarks and a wide array of symptoms. However, both of the diseases in the early stages share some common hallmarks, including alterations in the ER and mitochondrial Ca2+ handling.
mitochondrial dysfunction and increased ROS production. Disturbances in Ca\textsuperscript{2+} signaling are central in the early pathophysiology of AD, as well as in WS. This indicates that similar mechanisms may underly these two diseases’ pathologies and suggests that both research topics might benefit from complementary research.

**Author Contributions:** Conceptualization, M.C. and J.L.; writing—original draft preparation, M.C. and J.L.; writing—review and editing, M.C., J.L., and G.B.; visualization, M.C.; supervision, G.B.; project administration, G.B.; funding acquisition, G.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** Research in the authors’ laboratory was funded by Bijzonder Onderzoeks Fonds KU Leuven (C14/19/099), the Research Foundation—Flanders (FWO: project numbers G0E7520N and G081821N and fellowship numbers: 11K7122N); Stichting Alzheimer Onderzoek (SAO IP3 receptor); Eye Hope Foundation/Koning Boudewijnstichting, grant number 2020-J1160630-214966.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Berridge, M.J.; Lipp, P.; Bootman, M.D. The versatility and universality of calcium signalling. *Nat Rev Mol Cell Biol* **2000**, *1*, 11–21. doi:10.1038/35036035.

2. Bootman, M.D.; Bultynck, G. Fundamentals of Cellular Calcium Signaling: A Primer. *Cold Spring Harb Perspect Biol* **2020**, *12*. https://doi.org/10.1101/cshperspect.a038802.

3. Rizzuto, R.; De Stefani, D.; Raffaello, A.; Mammucari, C. Mitochondria as sensors and regulators of calcium signalling. *Nature Revies Molecular Cell Biology* **2012**, *13*, 566–578. https://doi.org/10.1038/nrm3412.

4. Parys, J.B.; Guse, A.H. Full focus on calcium. *Sci Signal* **2019**, *12*. https://doi.org/10.1126/scisignal.aaz0961.

5. Brini, M.; Calì, T.; Ottolini, D.; Carafoli, E. Neuronal calcium signaling: Function and dysfunction. *Cellular and Molecular Life Sciences* **2014**, *71*, 2787–2814. https://doi.org/10.1007/s00018-013-1550-7.

6. Parys, J.B.; Vervliet, T. New Insights in the IP3 Receptor and Its Regulation. *Adv Exp Med Biol* **2020**, *1131*, 243–270. https://doi.org/10.1007/978-3-030-12457-1_10.

7. Woll, K.A.; Van Petegem, F. Calcium-release channels: structure and function of IP\textsubscript{3} receptors and ryanodine receptors. *Physiol Rev* **2022**, *102*, 209–268. https://doi.org/10.1152/physrev.00033.2020.

8. Lanner, J.T.; Georgiou, D.K.; Joshi, A.D.; Hamilton, S.L. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. *Cold Spring Harb Perspect Biol* **2010**, *2*, a003996. https://doi.org/10.1101/cshperspect.a003996.

9. Bandara, S.; Malmersjo, S.; Meyer, T. Regulators of calcium homeostasis identified by inference of kinetic model parameters from live single cells perturbed by siRNA. *Sci Signal* **2013**, *6*, ra56. https://doi.org/10.1126/scisignal.2003649.

10. Lemos, F.O.; Bultynck, G.; Parys, J.B. A comprehensive overview of the complex world of the endo- and sarcoplasmic reticulum Ca\textsuperscript{2+}-leak channels. *Biochim Biophys Acta Mol Cell Res* **2021**, *1868*, 119020. https://doi.org/10.1016/j.bbamcr.2021.119020.

11. Tu, H.; Nelson, O.; Bezprozvanny, A.; Wang, Z.; Lee, S.F.; Hao, Y.H.; Semeels, L.; De Strooper, B.; Yu, G.; Bezprozvanny, I. Presenilins form ER Ca\textsuperscript{2+} leak channels, a function disrupted by familial Alzheimer’s disease-linked mutations. *Cell* **2006**, *126*, 981–993. https://doi.org/10.1016/j.cell.2006.06.059.

12. Wang, Q.C.; Zheng, Q.; Tan, H.; Zhang, B.; Li, X.; Yang, Y.; Yu, J.; Liu, Y.; Chai, H.; Wang, X.; et al. TMCO1 Is an ER Ca\textsuperscript{2+} Load-Activated Ca\textsuperscript{2+} Channel. *Cell* **2016**, *165*, 1454–1466. https://doi.org/10.1016/j.cell.2016.04.051.

13. Chen, J.; Sitsel, A.; Benoy, V.; Sepulveda, M.R.; Vangheluwe, P. Primary Active Ca\textsuperscript{2+} Transport Systems in Health and Disease. *Cold Spring Harb Perspect Biol* **2020**, *12*. https://doi.org/10.1101/cshperspect.a035113.

14. Lewis, R.S. Store-Operated Calcium Channels: From Function to Structure and Back Again. *Cold Spring Harb Perspect Biol* **2020**, *12*. https://doi.org/10.1101/cshperspect.a035055.

15. Baraniak, J.H., Jr.; Zhou, Y.; Nwokonko, R.M.; Jennette, M.R.; Kazzaz, S.A.; Stenson, J.M.; Whitbell, A.L.; Wang, Y.; Trebak, M.; Gill, D.L. Orai channel C-terminal peptides are key modulators of STIM-Orai coupling and calcium signal generation. *Cell Rep* **2021**, *35*, 109322. https://doi.org/10.1016/j.celrep.2021.109322.

16. Emrich, S.M.; Yoast, R.E.; Xin, P.; Arige, V.; Wagner, L.E.; Hempel, N.; Gill, D.L.; Sneyd, J.; Yule, D.I.; Trebak, M. Omnimtemporal choreographies of all five STIM/Orai and IP\textsubscript{3}Rs underlie the complexity of mammalian Ca\textsuperscript{2+} signaling. *Cell Rep* **2021**, *34*, 108760. https://doi.org/10.1016/j.celrep.2021.108760.
17. Ahmad, M.; Ong, H.L.; Saadi, H.; Son, G.Y.; Shokatian, Z.; Terry, L.E.; Trebak, M.; Yule, D.I.; Ambudkar, I. Functional communication between IP3R and STIM2 at subthreshold stimuli is a critical checkpoint for initiation of SOCE. *Proc Natl Acad Sci USA* 2022, 119. https://doi.org/10.1073/pnas.2114928118.

18. Brini, M.; Carafoli, E. The plasma membrane Ca2+ ATPase and the plasma membrane sodium calcium exchanger cooperate in the regulation of cell calcium. *Cold Spring Harb Perspect Biol* 2013, 5, 1–16. https://doi.org/10.1101/cshperspect.a004168.

19. Kasri, N.N.; Bultynck, G.; Smyth, J.; Szulc, K.; Parys, J.B.; Callewaert, G.; Missiaen, L.; Fissore, R.A.; Mikoshiba, K.; de Smert, H. The N-terminal Ca2+-independent calmodulin-binding site on the inositol 1,4,5-trisphosphate receptor is responsible for calmodulin inhibition, even though this inhibition requires Ca2+. *Mol Pharmacol* 2004, 66, 276–284. https://doi.org/10.1124/mol.66.2.276.

20. Nadif Kasri, N.; Bultynck, G.; Sienaert, I.; Callewaert, G.; Erneux, C.; Missiaen, L.; Parys, J.B.; de Smert, H. The role of calmodulin for inositol 1,4,5-trisphosphate receptor function. *Biochim Biophys Acta* 2020, 1865, 1–15. https://doi.org/10.1016/j.bbamcr.2014.10.029.

21. Schwaller, B. Cytosolic Ca2+ Buffers Are Inherently Ca2+ Signal Modulators. *Cold Spring Harb Perspect Biol* 2020, 12. https://doi.org/10.1101/cshperspect.a035543.

22. Elies, J.; Yanez, M.; Pereira, T.M.C.; Gil-Longo, J.; MacDougall, D.A.; Campos-Toimil, M. An Update to Calcium Binding Proteins. *Adv Exp Med Biol* 2020, 1131, 183–213. https://doi.org/10.1007/978-3-030-12457-1_8.

23. Burgoyne, R.D.; Haynes, L.P. Sense and specificity in neuronal calcium signalling. *Biochim Biophys Acta* 2015, 1853, 1921–1932. https://doi.org/10.1016/j.bbamcr.2014.10.029.

24. Kasri, N.N.; Holmes, A.M.; Bultynck, G.; Parys, J.B.; Bootman, M.D.; Rietdorf, K.; Missiaen, L.; McDonald, F.; de Smert, H.; Conway, S.J.; et al. Regulation of InsP3 receptor activity by neuronal Ca2+-binding proteins. *EMBO J* 2004, 23, 312–321. https://doi.org/10.1038/sj.emboj.7600037.

25. Pivovarova, N.B.; Andrews, S.B. Calcium-dependent mitochondrial function and dysfunction in neurons. *FEBS J* 2010, 277, 3622–3636. https://doi.org/10.1111/j.1742-4658.2010.07754.x.

26. Kostic, M.; Sekler, I. Functional properties and mode of regulation of the mitochondrial Na+/Ca2+ exchanger, NCLX. *Cell Calcium* 2019, 54, 59–65. https://doi.org/10.1016/j.ceca.2019.01.009.

27. Katoshevski, T.; Ben-Kasus Nissim, T.; Sekler, I. Recent studies on NCLX in health and diseases. *Cell Calcium* 2021, 94, 102345. https://doi.org/10.1016/j.ceca.2020.102345.

28. Loncke, J.; Kaasik, A.; Bezprozvanny, I.; Parys, J.B.; Kerkhofs, M.; Bultynck, G. Balancing ER-Mitochondrial Ca2+ Fluxes in Health and Disease. *Trends Cell Biol* 2021, 31, 598–612. https://doi.org/10.1016/j.tcb.2021.02.003.

29. Cserdas, G.; Renken, C.; Varnai, P.; Walter, L.; Weaver, D.; Buttle, K.F.; Balla, T.; Mannella, C.A.; Hajnoczky, G. Structural and functional features and significance of the physical linkage between ER and mitochondria. *EMBO J* 2021, 40, e105830. https://doi.org/10.1038/s41592-020-00041-7.

30. Rizzuto, R.; Pinton, P.; Carrington, W.; Fay, F.S.; Fogarty, K.E.; Lifshitz, L.M.; Tuft, R.A.; Pozzan, T. Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. *Science* 1998, 280, 1763–1766. https://doi.org/10.1126/science.280.5370.1763.

31. Szabadkai, G.; Bianchi, K.; Vármai, P.; De Stefani, D.; Wieckowski, M.R.; Cavagna, D.; Nagy, A.I.; Balla, T.; Rizzuto, R. Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels. *Journal of Cell Biology* 2006, 175, 901–911. https://doi.org/10.1083/jcb.200608073.

32. Cárdenas, C.; Miller, R.A.; Smith, I.; Bui, T.; Molgó, J.; Müller, M.; Vais, H.; Cheung, K.H.; Yang, J.; Parker, I.; et al. Essential Regulation of Cell Bioenergetics by Constitutive InsP3 Receptor Ca2+ Transfer to Mitochondria. *Cell* 2010, 142, 270–283. https://doi.org/10.1016/j.cell.2010.06.007.

33. Filadi, R.; Leal, N.S.; Schreiner, B.; Rossi, A.; Dentoni, G.; Pinho, C.M.; Wiehager, B.; Cieri, D.; Calì, T.; Pizzo, P.; et al. TOM70 Sustains Cell Bioenergetics by Promoting IP3-Mediated ER to Mitochondria Ca2+ Transfer. *Current Biology* 2018, 28, 369–382.e366. https://doi.org/10.1016/j.cub.2017.12.047.

34. Wu, S.; Lu, Q.; Wang, Q.; Ding, Y.; Ma, Z.; Mao, X.; Huang, K.; Xie, Z.; Zou, M.H. Binding of FUN14 Domain Containing 1 With Inositol 1,4,5-Trisphosphate Receptor in Mitochondria-Associated Endoplasmic Reticulum Membranes Maintains Mitochondrial Dynamics and Function in Hearts in Vivo. *Circulation* 2017, 136, 2248–2266. https://doi.org/10.1161/CIRCULATIONAHA.117.032035.

35. Carreras-Sureda, A.; Jaña, F.; Urria, H.; Durand, S.; Mortensen, D.E.; Sagredo, A.; Bustos, G.; Hazari, Y.; Ramos-Fernández, E.; Sassano, M.L.; et al. Non-canonical function of IRE1α determines mitochondria-associated endoplasmic reticulum composition to control calcium transfer and bioenergetics. *Nature Cell Biology* 2019, 21, 755–767. https://doi.org/10.1038/s41564-019-0329-y.

36. Bartok, A.; Weaver, D.; Golenar, T.; Nichotova, Z.; Katona, M.; Bansaghi, S.; Alzayed, K.J.; Thomas, V.K.; Ando, H.; Mikoshiba, K.; et al. IP3 receptor isoforms differently regulate ER-mitochondrial contacts and local calcium transfer. *Nat Commun* 2019, 10, 3726. https://doi.org/10.1038/s41467-019-11646-3.

37. Decuyper, J.P.; Bultynck, G.; Parys, J.B. A dual role for Ca2+ in autophagy regulation. *Cell Calcium* 2011, 50, 242–250. https://doi.org/10.1016/j.cca.2011.04.001.

38. Giorgi, C.; Marchi, S.; Pinton, P. The machineries, regulation and cellular functions of mitochondrial calcium. *Nat Rev Mol Cell Biol* 2018, 19, 713–730. https://doi.org/10.1038/s41580-018-0052-8.

39. Giorgi, V.; Guo, L.; Bassot, C.; Petronilli, V.; Bernardi, P. Calcium and regulation of the mitochondrial permeability transition. *Cell Calcium* 2018, 70, 56–63. https://doi.org/10.1016/j.ceca.2017.05.004.
40. Hwang, M.S.; Schwall, C.T.; Pazarentzos, E.; Datler, C.; Alder, N.N.; Grimm, S. Mitochondrial Ca²⁺ influx targets cardioliopin to disintegrate respiratory chain complex II for cell death induction. Cell Death and Differentiation 2014, 21, 1733–1745. https://doi.org/10.1038/cdd.2014.84.

41. Cai, Q.; Tammineni, P. Mitochondrial Aspects of Systopic Dysfunction in Alzheimer’s Disease. J Alzheimers Dis 2017, 57, 1087–1103. https://doi.org/10.3233/JAD-160726.

42. Hayashi, T.; Su, T.P. Sigma-1 Receptor Chaperones at the ER- Mitochondron Interface Regulate Ca²⁺ Signaling and Cell Survival. Cell 2007, 131, 596–610. https://doi.org/10.1016/j.cell.2007.08.036.

43. Anelli, T.; Bergamelli, L.; Margittai, E.; Rimessi, A.; Fagioli, C.; Malgaroli, A.; Pinton, P.; Ripamonti, M.; Rizzuto, R.; Sitia, R. Ero1alpha regulates Ca²⁺ fluxes at the endoplasmic reticulum-mitochondria interface (MAM). Antioxid Redox Signal 2012, 16, 1077–1087. https://doi.org/10.1089/ars.2011.4004.

44. Booth, D.M.; Enyedi, B.; Geiszt, M.; Varnai, P.; Hajnoczky, G. Redox Nanodomains Are Induced by and Control Calcium Signaling at the ER-Mitochondrial Interface. Mol Cell 2016, 63, 240–248. https://doi.org/10.1016/j.molcel.2016.05.040.

45. Booth, D.M.; Varnai, P.; Joseph, S.K.; Hajnoczky, G. Oxidative bursts of single mitochondria mediate retrograde signaling toward the ER. Mol Cell 2021, 81, 3866–3876 e3862. https://doi.org/10.1016/j.molcel.2021.07.014.

46. Joseph, S.K.; Young, M.P.; Alzayady, K.; Yule, D.I.; Ali, M.; Booth, D.M.; Hajnoczky, G. Redox regulation of type-I inositol trisphosphate receptors in intact mammalian cells. J Biol Chem 2018, 293, 17464–17476. https://doi.org/10.1074/jbc.RA118.005624.

47. Zhang, J.; Guan, X.; Shah, K.; Yan, J. Lsm12 is an NAADP receptor and a two-pore channel regulatory protein required for calcium mobilization from acidic organelles. Nat Commun 2021, 12, 4739. https://doi.org/10.1038/s41467-021-24735-z.

48. Marchant, J.S.; Gunaratne, G.S.; Cai, X.; Slama, J.T.; Patel, S. NAADP-binding proteins find their identity. Trends Biochem Sci 2022, 47, 235–249. https://doi.org/10.1016/j.tibs.2021.10.008.

49. Patel, S.; Yuan, Y.; Gunaratne, G.S.; Rahman, T.; Marchant, J.S. Activation of endo-lysosomal two-pore channels by NAADP and PI(3,5)P2. Five things to know. Biochem J 2011, 439, 349–374. https://doi.org/10.1042/Bj20110949.

50. Gallione, A. A primer of NAADP-mediated Ca²⁺ signalling: From sea urchin eggs to mammalian cells. Cell Calcium 2015, 58, 27–47. https://doi.org/10.1016/j.ceca.2014.09.010.

51. Gunaratne, G.S.; Brailoiu, E.; He, S.; Unterwald, E.M.; Patel, S.; Slama, J.T.; Walseth, T.F.; Marchant, J.S. Essential requirement for JPT2 in NAADP-evoked Ca²⁺ signaling. Sci Signal 2014, 7. https://doi.org/10.1126/esci.signal.abb5605.

52. Zhang, J.; Guan, X.; Shah, K.; Yan, J. Lsm12 is an NAADP receptor and a two-pore channel regulatory protein required for calcium mobilization from acidic organelles. Nat Commun 2021, 12, 4739. https://doi.org/10.1038/s41467-021-24735-z.

53. Marchant, J.S.; Gunaratne, G.S.; Cai, X.; Slama, J.T.; Patel, S. NAADP-binding proteins find their identity. Trends Biochem Sci 2022, 47, 235–249. https://doi.org/10.1016/j.tibs.2021.10.008.

54. Patel, S.; Yuan, Y.; Gunaratne, G.S.; Rahman, T.; Marchant, J.S. Activation of endo-lysosomal two-pore channels by NAADP and PI(3,5)P2. Five things to know. Cell Calcium 2022, 103, 102543. https://doi.org/10.1016/j.ceca.2022.102543.

55. Gu, F.; Kruger, A.; Roggenkamp, H.G.; Alpers, R.; Lodygin, D.; Jaquet, V.; Mockl, F.; Hernandez, C.L.; Winterberg, K.; Bauche, A.; et al. Dual NADPH oxidases DUOX1 and DUOX2 synthesize NAADP and are necessary for Ca²⁺ signaling during T cell activation. Sci Signal 2021, 14, eabe3800. https://doi.org/10.1126/scisignal.abe3800.

56. Serge Gauthier, P.R.-N.; Jose A. Morais, Claire Webster. World Alzheimer Report 2021: Journey through the diagnosis of dementia. Available online: https://www.alz.org/u/world-Alzheimer-Report-2021.pdf (accessed on 03/02/2022).

57. van Bernhardi, R.; Tichauer, J.E.; Eugenin, J. Aging-dependent changes of microglial cells and their relevance for neurodegenerative disorders. J Neurochem 2010, 112, 1099–1114. https://doi.org/10.1111/j.1471-4159.2009.06397.x.

58. van Bernhardi, R.; Tichauer, J.E.; Eugenin, J. Aging-dependent changes of microglial cells and their relevance for neurodegenerative disorders. J Neurochem 2010, 112, 1099–1114. https://doi.org/10.1111/j.1471-4159.2009.06397.x.

59. van Gassen, G.; Annaert, W. Amyloid, presenilins, and Alzheimer’s disease. Neuroscientist 2003, 9, 117–126. https://doi.org/10.1046/j.1471-4159.2003.00200.x.

60. von Bernhardi, R.; Tichauer, J.E.; Eugenin, J. Aging-dependent changes of microglial cells and their relevance for neurodegenerative disorders. J Neurochem 2010, 112, 1099–1114. https://doi.org/10.1111/j.1471-4159.2009.06397.x.

61. van Gassen, G.; Annaert, W. Amyloid, presenilins, and Alzheimer’s disease. Neuroscientist 2003, 9, 117–126. https://doi.org/10.10117/1073858403252227.

62. Lucotte, G.; Visvikis, S.; Leininger-Muler, B.; David, F.; Berriche, S.; Reveilleau, S.; Couderc, R.; Babron, M.C.; Aguillon, D.; Siest, G. Association of apolipoprotein E allele epsilon 4 with late-onset sporadic Alzheimer’s disease. Am J Med Genet 1994, 54, 286–288. https://doi.org/10.1002/ajmg.1320540319.

63. van der Lee, S.J.; Wolters, F.J.; Ikram, M.K.; Hofman, A.; Ikram, M.A.; Amin, N.; van Duijn, C.M. The effect of APOE and other common genetic variants on the onset of Alzheimer’s disease and dementia: a community-based cohort study. Lancet Neurol 2018, 17, 434–444. https://doi.org/10.1016/S1474-4422(18)30053-X.

64. Kumar, D.; Ganeshpurkar, A.; Kumar, D.; Modi, G.; Gupta, S.K.; Singh, S.K. Secretase inhibitors for the treatment of Alzheimer’s disease: Long road ahead. Eur J Med Chem 2018, 148, 436–452. https://doi.org/10.1016/j.ejmech.2018.02.035.

65. Lalli, G.; Schott, J.M.; Hardy, J.; De Strooper, B. Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? EMBO Mol Med 2021, 13, e14781. https://doi.org/10.15252/emmm.202114781.
66. Velazquez, R.; Ferreira, E.; Knowles, S.; Fux, C.; Rodin, A.; Winslow, W.; Oddo, S. Lifelong choline supplementation ameliorates Alzheimer’s disease pathology and associated cognitive deficits by attenuating microglia activation. *Aging Cell* 2019, 18, e13037. https://doi.org/10.1111/agec.13037.

67. An, Y.; Qi, Y.; Li, Y.; Li, Z.; Yang, C.; Jia, D. Activation of the sigma-1 receptor attenuates blood-brain barrier disruption by inhibiting amyloid deposition in Alzheimer’s disease mice. *Neurosci Lett* 2022, 774, 136528. https://doi.org/10.1016/j.neulet.2022.136528.

68. Hardy, J.A.; Higgins, G.A. Alzheimer’s disease: The amyloid cascade hypothesis. *Science* 1992, 256, 184–185. https://doi.org/10.1126/science.1566067.

69. Selkoe, D.J.; Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. *EMBO Mol Med* 2016, 8, 595–608. https://doi.org/10.15252/emmm.201606210.

70. Ricciarelli, R.; Fedele, E. The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind. *Curr Neuropharmacol* 2017, 15, 926–935. https://doi.org/10.2174/1570159X15666170116143743.

71. Aizenstein, H.J.; Nebes, R.D.; Saxton, J.A.; Price, J.C.; Mathis, C.A.; Tsopelas, N.D.; Ziolko, S.K.; James, J.A.; Snitz, B.E.; Houck, P.R.; et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. *Arch Neurol* 2008, 65, 1509–1517. https://doi.org/10.1001/archneur.65.11.1509.

72. Villemagne, V.L.; Pike, K.E.; Chetelat, G.; Ellis, K.A.; Mulligan, R.S.; Bourgeat, P.; Ackermann, U.; Jones, G.; Szeoke, C.; Salvado, O.; et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. *Ann Neurol* 2011, 69, 181–192. https://doi.org/10.1002/ana.22248.

73. Price, J.L.; McKeel, D.W., Jr.; Buckles, V.D.; Roe, C.M.; Grundman, M.; Hansen, L.A.; Petersen, R.C.; Parisi, J.E.; Dickson, D.W.; et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. *Neurobiol Aging* 2009, 30, 1026–1036. https://doi.org/10.1016/j.neurobiolaging.2009.04.002.

74. Morris, G.P.; Clark, I.A.; Vissel, B. Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer’s Disease. *Acta Neuropathologica Communications* 2014, 2, 135. https://doi.org/10.1186/s40478-014-0135-5.

75. Khachaturian, Z.S. Calcium hypothesis of Alzheimer’s disease and brain aging. *Arch Neurol* 2012, 69, 1741–1746. https://doi.org/10.1001/archneur.69.11.1741.

76. Berridge, M.J. Calcium hypothesis of Alzheimer’s disease. *Pflugers Arch* 2010, 459, 441–449. https://doi.org/10.1007/s00424-009-0736-1.

77. McDaid, J.; Mustaly-Kalimi, S.; Stutzmann, G.E. Ca<sup>2+</sup> Dyshomeostasis Disrupts Neuronal and Synaptic Function in Alzheimer’s Disease. *Cells* 2020, 9, https://doi.org/10.3390/cells9122655.

78. Popugaeva, E.; Chernyuk, D.; Bezprozvanny, I. Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer’s Disease. *Curr Alzheimer Res* 2020, 17, 344–354. https://doi.org/10.2174/1567205017666200528162046.

79. Workgroup, A.s.A.C.H. Calcium Hypothesis of Alzheimer’s disease and brain aging: A framework for integrating new evidence into a comprehensive theory of pathogenesis. *Alzheimer’s and Dementia* 2017, 13, 178-182.e117. https://doi.org/10.1016/j.jalz.2016.12.006.

80. Berridge, M.J. Calcium signalling and Alzheimer’s disease. *Neurochemical Research* 2011, 36, 1149–1156. https://doi.org/10.1007/s11064-010-0371-4.

81. Agostini, M.; Fasolato, C. When, where and how? Focus on neuronal calcium dysfunctions in Alzheimer’s Disease. *Cell Calcium* 2016, 60, 289–298. https://doi.org/10.1016/j.ceca.2016.06.008.

82. Schrank, S.; Barrington, N.; Stutzmann, G.E. Calcium-Handling Defects and Neurodegenerative Disease. *Cold Spring Harb Perspect Biol* 2020, 12. https://doi.org/10.1101/cshperspect.a035212.

83. Drees-Werringloer, U.; Lambert, J.C.; Vingtdeux, V.; Zhao, H.; Vais, H.; Siebert, A.; Jain, A.; Koppel, J.; Rovelet-Lecrux, A.; Hannequin, D.; et al. A polymorphism in CALHM1 influences Ca<sup>2+</sup> homeostasis, Abeta levels, and Alzheimer’s disease risk. *Acta Neuropathologica Communications* 2016, 30, 1149–1161. https://doi.org/10.1186/s40478-016-0438-x.

84. Green, K.N.; LaFerla, F.M. Linking calcium to Abeta and Alzheimer’s disease. *Neuron* 2008, 59, 190–194. https://doi.org/10.1016/j.neuron.2008.07.013.

85. Ma, Z.; Siebert, A.P.; Cheung, K.-H.; Lee, R.J.; Johnson, B.; Cohen, A.S.; Vingtdeux, V.; Marambaud, P.; Foskett, J.K. Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca<sup>2+</sup><sub>sup</sub><sup>&lt;</sup> <sup>&lt;</sup>sup>sup</sup> regulation of neuronal excitability. *Proceedings of the National Academy of Sciences* 2012, 109, E1963-E1971, doi:10.1073/pnas.120403109.

86. Ma, Z.; Tanis, J.E.; Taruno, A.; Foskett, J.K. Calcium homeostasis modulator (CALHM) ion channels. *Pflugers Arch* 2016, 468, 395–403. https://doi.org/10.1007/s00424-015-1757-6.

87. Kuchibhotla, K.V.; Goldman, S.T.; Lattarulo, C.R.; Wu, H.Y.; Hyman, B.T.; Bacsikai, B.J. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. *Neuron* 2008, 59, 214–225. https://doi.org/10.1016/j.neuron.2008.06.008.

88. Lopez, J.R.; Lyckman, A.; Oddo, S.; Laferla, F.M.; Querfurth, H.W.; Shifman, A. Increased intraneuronal resting [Ca<sup>2+</sup>]<sub>in</sub> in adult Alzheimer’s disease mice. *J Neurochem* 2012, 120, 262–271. https://doi.org/10.1111/j.1471-4159.2012.05135.x.

89. Cheung, K.H.; Shineman, D.; Müller, M.; Cárdenas, C.; Mei, L.; Yang, J.; Tomita, T.; Iwatsubo, T.; Lee, V.M.Y.; Foskett, J.K. Mechanism of Ca<sup>2+</sup> Disruption in Alzheimer’s Disease by Presenilin Regulation of InsP<sub>3</sub> Receptor Channel Gating. *Neuron* 2008, 58, 871–883. https://doi.org/10.1016/j.neuron.2008.04.015.
90. Cheung, K.H.; Mei, L.; Mak, D.O.; Hayashi, I.; Iwatsubo, T.; Kang, D.E.; Foskett, J.K. Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer’s disease-linked presenilin mutants in human cells and mouse neurons. *Sci Signal* **2010**, *3*, ra22. https://doi.org/10.1126/scisignal.2000818.

91. Klee, C.; Madreiter-Sokolowsk, C.T.; Stryeck, S.; Sachdev, V.; Duta-Mare, M.; Gottschalk, B.; Depaoli, M.R.; Rost, R.; Hay, J.; Waldeck-Weiermair, M.; et al. Glycogen Synthase Kinase 3 Beta Controls Presenilin-1-Mediated Endoplasmic Reticulum Ca2+ Leak Directed to Mitochondria in Pancreatic Islets and beta-Cells. *Cell Physiol Biochem* **2019**, *52*, 57–75. https://doi.org/10.33594/00000005.

92. Foskett, J.K.; Daniel Mak, D.O. Regulation of IP(3)R Channel Gating by Ca2+ and Ca2+ Binding Proteins. *Curr Top Membr* **2010**, *66*, 235–272. https://doi.org/10.1007/978-3-642-06611-5.

93. Stutzmann, G.E.; Caccamo, A.; LaFerla, F.M.; Parker, I. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer’s-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. *J Neurosci* **2004**, *24*, 508–513. https://doi.org/10.1523/JNEUROSCI.4386-03.2004.

94. Jensen, L.E.; Bultynck, G.; Luyten, T.; Amijee, H.; Bootman, M.D.; Roderick, H.L. Alzheimer’s disease-associated peptide Abeta42 mobilizes ER Ca2+ via InsP3R-dependent and -independent mechanisms. *Front Mol Neurosci* **2013**, *6*, 36. https://doi.org/10.3389/fnmol.2013.00036.

95. Chan, S.L.; Mayne, M.; Holden, C.P.; Geiger, J.D.; Mattson, M.P. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. *J Biol Chem* **2000**, *275*, 18195–18200. https://doi.org/10.1074/jbc.M00040200.

96. Smith, I.F.; Hitt, B.; Green, K.N.; Oddo, S.; LaFerla, F.M. Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer’s disease. *J Neurochem* **2005**, *94*, 1711–1718. https://doi.org/10.1111/j.1471-4159.2005.03332.x.

97. Kelliber, M.; Fastbom, J.; Cowburn, R.F.; Bonkale, W.; Ohm, T.G.; Ravid, R.; Serrentino, V.; O’Neill, C. Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer’s disease neurofibrillary and beta-amyloid pathologies. *Neuroscience* **1999**, *92*, 499–513. https://doi.org/10.1016/S0364-5622(99)00042-1.

98. Stutzmann, G.E.; Smith, I.; Caccamo, A.; Oddo, S.; LaFerla, F.M.; Parker, I. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer’s disease mice. *J Neurosci* **2006**, *26*, 5180–5189. https://doi.org/10.1523/JNEUROSCI.0739-06.2006.

99. Chakroborty, S.; Goussakov, I.; Miller, M.B.; Stutzmann, G.E. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. *J Neurosci* **2009**, *29*, 9458–9470. https://doi.org/10.1523/JNEUROSCI.2407-09.2009.

100. Hermus, J.; Schneider, I.; Dewachter, I.; Caluwaerts, N.; Kretzschmar, H.; Van Leuven, F. Capacitive calcium entry is directly attenuated by mutant presenilin-1, independent of the expression of the amyloid precursor protein. *J Biol Chem* **2003**, *278*, 2484–2489. https://doi.org/10.1074/jbc.M200679200.

101. Yoo, A.S.; Cheng, I.; Chung, S.; Grenfell, T.Z.; Lee, H.; Pack-Chung, E.; Handler, M.; Shen, J.; Xia, W.; Tesco, G.; et al. Presenilin-mediated modulation of capacitative calcium entry. *Neuron* **2000**, *27*, 561–572. https://doi.org/10.1016/S0896-6273(00)00066-0.

102. Leissring, M.A.; Akbari, Y.; Fanger, C.M.; Cahalan, M.D.; Mattson, M.P.; LaFerla, F.M. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. *J Cell Biol* **2000**, *149*, 793–798. https://doi.org/10.1083/jcb.149.4.793.

103. Liguri, G.; Cecchi, C.; Latorraca, S.; Pieri, A.; Sorbi, S.; Degl’Innocenti, D.; Ramponi, G. Alteration of acylphosphatase levels in familial Alzheimer’s disease fibroblasts with presenilin gene mutations. *Neurosci Lett* **1996**, *210*, 153–156. https://doi.org/10.1016/0304-3940(96)12696-3.

104. Green, K.N.; Demuro, A.; Akbari, Y.; Hitt, B.D.; Smith, I.F.; Parker, I.; LaFerla, F.M. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. *J Cell Biol* **2008**, *181*, 1107–1116. https://doi.org/10.1083/jcb.200706171.

105. LaFerla, F.M. Calcium dysthomeostasis and intracellular signalling in alzheimer’s disease. *Nature Reviews Neuroscience* **2002**, *3*, 862–872. https://doi.org/10.1038/nrn9680.

106. Querfurth, H.W.; Selkoe, D.J. Calcium Ionophore Increases Amyloid β Peptide Production by Cultured Cells. *Biochemistry* **1994**, *33*, 4550–4561. https://doi.org/10.1021/bi00181a016.

107. Calvo-Rodriguez, M.; Khairitonova, E.K.; Bacsai, B.J. In vivo brain imaging of mitochondrial Ca2+ in neurodegenerative diseases with multiphoton microscopy. *Biochim Biophys Acta Mol Cell Res* **2021**, *1868*, 118998. https://doi.org/10.1016/j.bbamcr.2021.118998.

108. Yao, J.; Irwin, R.W.; Zhao, L.; Nilsen, J.; Hamilton, R.T.; Brinton, R.D. Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. *Proc Natl Acad Sci U S A* **2009**, *106*, 14670–14675. https://doi.org/10.1073/pnas.0903563106.

109. Kopeikina, K.J.; Carlson, G.A.; Pitstick, R.; Ludvigson, A.E.; Peters, A.; Luebke, J.I.; Koffie, R.M.; Frosch, M.P.; Hyman, B.T.; Spiers-Jones, T.L. Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer’s disease brain. *Am J Pathol* **2011**, *179*, 2071–2082. https://doi.org/10.1016/j.ajpath.2011.07.004.

110. Atamna, H.; Frey, W.H., 2nd. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer’s disease. *Mitochondrion* **2007**, *7*, 297–310. https://doi.org/10.1016/j.mito.2007.06.001.

111. Xie, H.; Guan, J.; Borrelli, L.A.; Xu, J.; Serrano-Pozo, A.; Bacsai, B.J. Mitochondrial alterations near amyloid plaques in an Alzheimer’s disease mouse model. *J Neurosci* **2013**, *33*, 17042–17051. https://doi.org/10.1523/JNEUROSCI.1863-13.2013.
112. Calvo-Rodriguez, M.; Baekskai, B.J. Mitochondria and Calcium in Alzheimer's Disease: From Cell Signaling to Neuronal Cell Death. *Trends Neurosci* 2020. https://doi.org/10.1016/j.tins.2020.10.004.

113. Hansson Petersen, C.A.; Alikhani, N.; Behbahani, H.; Wiehager, B.; Pavlov, P.F.; Alafuozoff, I.; Leinonen, V.; Itø, A.; Winblad, B.; Glaser, E.; et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. *Proc Natl Acad Sci U S A* 2008, 105, 13145–13150. https://doi.org/10.1073/pnas.0806192105.

114. Calvo-Rodriguez, M.; Hou, S.S.; Snyder, A.C.; Kharitonova, E.K.; Russ, A.N.; Das, S.; Fan, Z.; Muzikansky, A.; Garcia-Alloza, M.; Serrano-Pozo, A.; et al. Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer's disease. *Nat Commun* 2020, 11, 2146. https://doi.org/10.1038/s41467-020-16074-2.

115. Cali, T.; Ottolini, D.; Brini, M. Mitochondrial Ca$^{2+}$ and neurodegeneration. *Cell Calcium* 2012, 52, 73–85. https://doi.org/10.1016/j.cca.2012.04.015.

116. Arispe, N.; Rojas, E.; Pollard, H.B. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. *Proc Natl Acad Sci U S A* 1993, 90, 567–571. https://doi.org/10.1073/pnas.90.2.567.

117. Kagan, B.L.; Hirakura, Y.; Azimov, R.; Azimova, R.; Lin, M.C. The channel hypothesis of Alzheimer's disease: current status. *Peptides* 2002, 23, 1311–1315. https://doi.org/10.1016/s0196-9781(02)00667-0.

118. Baughman, J.M.; Perocci, F.; Girgis, H.S.; Plovanich, M.; Belcher-Timme, C.A.; Sancak, Y.; Bao, X.R.; Strittmatter, L.; Goldberger, O.; Bogorad, R.L.; et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. *Nature* 2011, 476, 341–345. https://doi.org/10.1038/nature10234.

119. Venugopal, A.; Iyer, M.; Balasubramanian, V.; Vellingiri, B. Mitochondrial calcium uniporter as a potential therapeutic strategy for Alzheimer's disease. *Acta Neuropathol* 2020, 32, 65–71. https://doi.org/10.1007/neu.2019.39.

120. Bell, S.M.; Barnes, K.; De Marco, M.; Shaw, P.J.; Ferraiauolo, L.; Blackburn, D.J.; Venneri, A.; Mortiboys, H. Mitochondrial Dysfunction in Alzheimer's Disease: A Biomarker of the Future? *Biomedicines* 2021, 9. https://doi.org/10.3390/biomedicines9010063.

121. Jadiya, P.; Kolmetzky, D.W.; Tomar, D.; Di Meco, A.; Lombardi, A.A.; Lambert, J.P.; Luongo, T.S.; Ludtmann, M.H.; Pratico, D.; Elrod, J.W. Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease. *Nat Commun* 2019, 10, 3885. https://doi.org/10.1038/s41467-019-11813-6.

122. Britti, E.; Ros, J.; Esteras, N.; Abramov, A.Y. Tau inhibits mitochondrial calcium efflux and makes neurons vulnerable to calcium-induced cell death. *Cell Calcium* 2020, 86, 102150. https://doi.org/10.1016/j.cca.2019.102150.

123. Yan, S.D.; Stern, D.M. Mitochondrial dysfunction and Alzheimer's disease: role of amyloid-beta peptide alcohol dehydrogenase (ABAD). *Int J Exp Pathol* 2005, 86, 161–171. https://doi.org/10.1111/j.1099-9673.2005.00427.x.

124. Lustbader, J.W.; Cirilli, M.; Lin, C.; Xu, H.W.; Takuma, K.; Wang, N.; Caspersen, C.; Chen, X.; Pollak, S.; Chaney, M.; et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. *Science* 2004, 304, 448–452. https://doi.org/10.1126/science.1091230.

125. Fernandes, T.; Resende, R.; Silva, D.F.; Marques, A.P.; Santos, A.E.; Cardoso, S.M.; Domingues, M.R.; Moreira, P.I.; Pereira, C.F. Structural and Functional Alterations in Mitochondria-Associated Membranes (MAMs) and in Mitochondria Activate Stress Response Mechanisms in an In Vitro Model of Alzheimer’s Disease. *Biomedicines* 2021, 9. https://doi.org/10.3390/biomedicines9080881.

126. Area-Gomez, E.; De Groof, A.J.C.; Beldagh, I.; Bird, T.D.; Gibson, G.E.; Koehler, C.M.; Yu, W.H.; Huff, D.E.; Yaffe, M.P.; Pon, L.A.; et al. Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. *American Journal of Pathology* 2009, 175, 1810–1816. https://doi.org/10.2353/ajpath.2009.090219.

127. Area-Gomez, E.; Del Carmen Lara Castillo, M.; Tambini, M.D.; Guardia-Laguarta, C.; De Groof, A.J.C.; Madra, M.; Ikenouchi, J.; Umeda, M.; Bird, T.D.; Sturley, S.L.; et al. Upreregulated function of mitochondria-associated ER membranes in Alzheimer disease. *EMBO J* 2012, 31, 4106–4123. https://doi.org/10.1038/emboj.2012.202.

128. Hedskog, L.; Pinho, C.M.; Filadi, R.; Ronnack, A.; Hertwig, L.; Wiehager, B.; Larssen, P.; Gellhaar, S.; Sandebring, A.; Westerlund, M.; et al. Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer's disease and related models. *Proc Natl Acad Sci U S A* 2013, 110, 7916–7921. https://doi.org/10.1073/pnas.1300677110.

129. Pera, M.; Larrea, D.; Guardia-Laguarta, C.; Montesinos, J.; Velasco, K.R.; Agrawal, R.R.; Xu, Y.; Chan, R.B.; Di Paolo, G.; Meher, M.F.; et al. Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease. *EMBO J* 2017, 36, 3356–3371. https://doi.org/10.15252/embr.201796797.

130. Vaillant-Beuchot, L.; Mary, A.; Pardossi-Piquard, R.; Bourgeois, A.; Lauritzen, I.; Eyyert, F.; Kinoshita, P.F.; Cazareth, J.; Badot, C.; Fragaki, K.; et al. Accumulation of amyloid precursor protein C-terminal fragments triggers mitochondrial structure, function, and mitophagy defects in Alzheimer’s disease models and human brains. *Acta Neuropathol* 2021, 141, 39–65. https://doi.org/10.1007/s00401-020-02234-7.

131. Lauritzen, I.; Pardossi-Piquard, R.; Bauer, C.; Brigham, E.; Abraham, J.D.; Ranaldi, S.; Fraser, P.; St-George-Hyslop, P.; Le Thuc, O.; Espin, V.; et al. The beta-secretase-derived C-terminal fragment of betaAPP, C99, but not Abeta, is a key contributor to early intraneuronal lesions in triple-transgenic mice hippocampus. *J Neurosci* 2012, 32, 16243-1655a. https://doi.org/10.1523/NEUROSCI.2775-12.2012.

132. Wolfram, D.J.a.W., H.P. Diabetes Mellitus and Simple Optic Atrophy among Siblings: Report on Four Cases. *Mayo Clinic Proceedings*. 1938, 715-718.

133. Delprat, B.; Maurice, T.; Delettre, C. Wolfram syndrome: MAMs’ connection? *Cell Death Dis* 2018, 9, 364. https://doi.org/10.1038/s41419-018-0406-3.
Cells 2022, 11, 1963

134. Urano, F. Wolfram Syndrome: Diagnosis, Management, and Treatment. *Curr Diab Rep* 2016, 16, 6. https://doi.org/10.1007/s11892-015-0702-6.

135. Fischer, T.T.; Ehrlich, B.E. Wolfram Syndrome: a Monogenic Model to Study Diabetes Mellitus and Neurodegeneration. *Curr Opin Physiol* 2020, 17, 115–123. https://doi.org/10.1016/j.cophys.2020.07.009.

136. Rigoli, L.; Di Bella, C. Wolfram syndrome 1 and Wolfram syndrome 2. *Curr Opin Pediatr* 2012, 24, 512–517. https://doi.org/10.1097/MOP.0b013e328354cddf.

137. Rigoli, L.; Bramanti, P.; Di Bella, C.; De Luca, F. Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. *Pediatr Res* 2018, 83, 921–929. https://doi.org/10.1038/pr.2018.17.

138. Tekko, T.; Lillevali, K.; Luuk, H.; Sutt, S.; Truu, L.; Ord, T.; Mols, M.; Varas, E. Initiation and developmental dynamics of Wfs1 expression in the context of neural differentiation and ER stress in mouse forebrain. *Int J Dev Neurosci* 2014, 35, 80–88. https://doi.org/10.1016/j.ijdevneu.2014.03.009.

139. Ueda, K.; Kawano, J.; Takeda, K.; Yujiri, T.; Tanabe, K.; Anno, T.; Akiyama, M.; Nozaki, J.; Yoshinaga, T.; Koizumi, A.; et al. Endoplasmic reticulum stress induces Wfs1 gene expression in pancreatic beta-cells via transcriptional activation. *Eur J Endocrinol* 2005, 153, 167–176. https://doi.org/10.1530/eje.1.01945.

140. Suzuki, N.; Hosoya, M.; Oishi, N.; Okano, H.; Fujioka, M.; Ogawa, K. Expression pattern of wolframin, the WFS1 (Wolfram syndrome-1 gene) product, in common marmoset (Callithrix jacchus) cochlea. *Neuroreport* 2016, 27, 833–836. https://doi.org/10.1097/NWR.0000000000000624.

141. Yamada, T.; Ishihara, H.; Tamura, A.; Takahashi, R.; Yamaguchi, S.; Takei, D.; Tokita, A.; Satake, C.; Tashiro, F.; Katagiri, H.; et al. WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic beta-cells. *Hum Mol Genet* 2006, 15, 1600–1609. https://doi.org/10.1093/hmg/ddl081.

142. Fonseca, S.G.; Fukuma, M.; Lipson, K.L.; Nguyen, L.X.; Allen, J.R.; Oka, Y.; Urano, F. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic beta-cells. *J Biol Chem* 2005, 280, 39609–39615. https://doi.org/10.1074/jbc.M507426200.

143. Sakakibara, Y.; Sekiya, M.; Fujisaki, N.; Quan, X.; Iijima, K.M. Knockdown of wfs1, a fly homolog of Wolfram syndrome 1, in the nervous system increases susceptibility to age- and stress-induced neuronal dysfunction and degeneration in Drosophila. *PloS Genet* 2018, 14, e1007196. https://doi.org/10.1371/journal.pgen.1007196.

144. Crouzier, L.; Richard, E.M.; Diez, C.; Alzaeem, H.; Denus, M.; Cubedo, N.; Glendenning, E.; Baxendale, S.; Liévens, J-C.; et al. Morphological, behavioral and cellular analyses revealed different phenotypes in Wolfram syndrome wfs1a and wfs1b zebrafish mutant lines. *Hum Molecular Genetics* 2022, https://doi.org/10.1093/hmg/ddac065.

145. Loncke, J.; Vervliet, T.; Parys, J.B.; Kaasik, A.; Bultynck, G. Uniting the divergent Wolfram syndrome-linked proteins WFS1 and CISD2 as modulators of Ca²⁺ signaling. *Sci Signal* 2021, 14, eabc6165. https://doi.org/10.1126/scisignal.abc6165.

146. Wang, C.H.; Chen, Y.F.; Wu, C.Y.; Chu, C.H.; Huang, Y.L.; Kao, C.H.; Lin, C.H.; Kao, L.S.; Tsai, T.F.; Wei, Y.H. Cisd2 modulates the differentiation and functioning of adipocytes by regulating intracellular Ca²⁺ homeostasis. *Hum Mol Genet* 2014, 23, 4770–4785. https://doi.org/10.1093/hmg/ddu193.

147. Nechushlai, R.; Karmi, O.; Zuo, K.; Marjauli, H.B.; Darash-Yahana, M.; Sohn, Y.S.; King, S.D.; Zandalinas, S.I.; Carloni, P.; Mittler, R. The balancing act of NEET proteins: Iron, ROS, calcium and metabolism. *Biochim Biophys Acta Mol Cell Res* 2020, 1867, 118805. https://doi.org/10.1016/j.bbamcr.2020.118805.

148. Karmi, O.; Holt, S.H.; Song, L.; Tamir, S.; Luo, Y.; Bai, F.; Adenwalla, A.; Darash-Yahana, M.; Sohn, Y.S.; Jennings, P.A.; et al. Interactions between mitoNEET and NAF-1 in cells. *PLoS One* 2012, 7, e0175796. https://doi.org/10.1371/journal.pone.0175796.

149. Shen, Z.Q.; Huang, Y.L.; Teng, Y.C.; Wang, T.W.; Kao, C.H.; Yeh, C.H.; Tsai, T.F. CISD2 maintains cellular homeostasis. *Biochim Biophys Acta Mol Cell Res* 2021, 1868, 118954. https://doi.org/10.1016/j.bbamcr.2021.118954.

150. Chen, Y.F.; Chou, T.Y.; Lin, I.H.; Chen, C.G.; Kao, C.H.; Huang, G.J.; Chen, L.K.; Wang, P.N.; Lin, C.P.; Tsai, T.F. Upregulation of Cisd2 attenuates Alzheimer’s-related neuronal loss in mice. *J Pathol* 2020, 250, 299–311. https://doi.org/10.1002/path.5374.

151. Sun, C.C.; Lee, S.Y.; Kao, C.H.; Chen, L.H.; Shen, Z.Q.; Lai, C.H.; Tzeng, T.Y.; Pang, J.S.; Chiu, W.T.; Tsai, T.F. Cisd2 plays an essential role in corneal epithelial regeneration. *EBioMedicine* 2021, 74, 103654. https://doi.org/10.1016/j.ebiomedi.2021.103654.

152. Snayers, F.; Loncke, J.; Bultynck, G. Keeping an eye on Ca²⁺ signalling to tackle dry eye diseases. *EBioMedicine* 2021, 74, 103741. https://doi.org/10.1016/j.ebiomedi.2021.103741.

153. Osman, A.A.; Saito, M.; Makepeace, C.; Permutt, M.A.; Schlesinger, P.; Mueckler, M. Wolframin expression induces novel ion channel activity in endoplasmic reticulum membranes and increases intracellular calcium. *J Biol Chem* 2003, 278, 52755–52762. https://doi.org/10.1074/jbc.M310331200.

154. Cagalinec, M.; Liiv, M.; Hodurova, Z.; Hickey, M.A.; Vaarmann, A.; Mandel, M.; Zeb, A.; Choubev, V.; Kuum, M.; Saffiulina, D.; et al. Role of Mitochondrial Dynamics in Neuronal Development: Mechanism for Wolfram Syndrome. *PLoS Biol* 2016, 14, e1002511. https://doi.org/10.1371/journal.pbiol.1002511.

155. Angebault, C.; Fauconnier, J.; Patergnani, S.; Rieusset, J.; Danese, A.; Affortit, C.A.; Jagodzinska, J.; Megy, C.; Quiles, M.; Cazevieille, C.; et al. ER-mitochondria cross-talk is regulated by the Ca²⁺ sensor NCS1 and is impaired in Wolfram syndrome. *Sci Signal* 2018, 71. https://doi.org/10.1126/scisignal.aaq1380.

156. Zatyka, M.; Da Silva Xavier, G.; Bellomo, E.A.; Leadbetter, W.; Astuti, D.; Smith, J.; Michelangeli, F.; Rutter, G.A.; Barrett, T.G. Sarco(endoplasmic reticulum ATPase is a molecular partner of Wolfram syndrome 1 protein, which negatively regulates its expression. *Hum Mol Genet* 2015, 24, 814–821. https://doi.org/10.1093/hmg/ddu499.
Ivanova, H.; Vervliet, T.; Monaco, G.; Terry, L.E.; Rosa, N.; Baker, M.R.; Parys, J.B.; Serysheva, I.I.; Yule, D.I.; Bultynck, G. Bcl-reticulum requires NAF-1.

Chang, N.C.; Nguyen, M.; Germain, M.; Shore, G.C. Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulum.

Nguyen, L.D.; Fischer, T.T.; Abreu, D.; Arroyo, A.; Urano, F.; Ehrlich, B.E. Calpain inhibitor and ibudilast rescue beta cell functions in a cellular model of Wolfram syndrome.

Neilson, A.; et al. A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome.

Abreu, D.; Stone, S.I.; Pearson, T.S.; Bucelli, R.C.; Simpson, A.N.; Hurst, S.; Brown, C.M.; Kries, K.; Onwumere, C.; Gu, H.; et al. A phase Ib/IIa clinical trial of dantrolene sodium in patients with Wolfram syndrome.

Chaussenot, A.; et al. A novel CISD2 mutation associated with a classical Wolfram syndrome phenotype alters Ca²⁺ homeostasis and ER-mitochondria interactions.

Ivanova, H.; Vervliet, T.; Monaco, G.; Terry, L.E.; Rosa, N.; Baker, M.R.; Parys, J.B.; Serysheva, I.I.; Yule, D.I.; Bultynck, G. Bcl-2-associated autophagy regulator Naf-1 required for maintenance of skeletal muscle.

Chang, N.C.; Nguyen, M.; Germain, M.; Shore, G.C. Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulum requires NAF-1.

Ivanova, H.; Vervliet, T.; Monaco, G.; Terry, L.E.; Rosa, N.; Baker, M.R.; Parys, J.B.; Serysheva, I.I.; Yule, D.I.; Bultynck, G. Bcl-2 protein family as modulators of IP₃ receptors and other organellar Ca²⁺ channels.

Shen, Y.L.; Shen, Q.Z.; Huang, C.H.; Teng, Y.C.; Lin, C.H.; Tsai, T.F. Cisd2 Protects the Liver from Oxidative Stress and Ameliorates Western Diet-Induced Nonalcoholic Fatty Liver Disease.

Distelhorst, C.W. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domains of IP₃ receptors.

Rong, Y.P.; Bultynck, G.; Aromolaran, A.S.; Zhong, F.; Parys, J.B.; De Smedt, H.; Migney, G.A.; Roderick, H.L.; Bootman, M.D.; Distelhorst, C.W. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP₃ receptor.

Tamir, S.; Rotem-Bamberger, S.; Katz, C.; Mercos, F.; Hailey, K.L.; Zuris, J.A.; Wang, C.; Conlan, A.R.; Lipper, C.H.; Paddock, M.L.; et al. Integrated strategy reveals the protein interface between cancer targets Bcl-2 and NAF-1.

de Ridder, I.; Kerkhofts, M.; Veettil, S.P.; Dehaen, W.; Bultynck, G. Cancer cell death strategies by targeting Bcl-2's BH4 domain.

Rong, Y.P.; Bultynck, G.; Aromolaran, A.S.; Zhong, F.; Parys, J.B.; De Smedt, H.; Migney, G.A.; Roderick, H.L.; Bootman, M.D.; Distelhorst, C.W. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP₃ receptor.

Li, S.M.; Chen, C.H.; Chen, Y.W.; Yen, Y.C.; Fang, W.T.; Tsai, F.Y.; Chang, J.L.; Shen, Y.Y.; Huang, S.F.; Chuu, C.P.; et al. Upregulation of CISD2 augments ROS contribution to tumorigenesis and poor prognosis of lung adenocarcinoma.

Wiley, S.E.; Andreyev, A.Y.; Divakaruni, A.S.; Karisch, R.; Perkins, G.; Wall, E.A.; van der Geer, P.; Chen, Y.F.; Tsai, T.F.; Simon, M.I.; et al. Wolfram Syndrome protein, Miner1, regulates sulphhydryl redox status, the unfolded protein response, and Ca²⁺ homeostasis.

Huang, Y.L.; Shen, Z.Q.; Huang, C.H.; Lin, C.H.; Tsai, T.F. Cisd2 slows down liver aging and attenuates age-related metabolic dysfunction in male mice.

Amr, S.; Heisey, C.; Zhang, M.; Xia, X.J.; Shows, K.H.; Ajjouni, K.; Pandya, A.; Satin, L.S.; El-Shanti, H.; Shiang, R. A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2.

Chen, Y.F.; Kao, C.H.; Chen, Y.T.; Wang, C.H.; Wu, C.Y.; Tsai, C.Y.; Liu, F.C.; Yang, C.W.; Wei, Y.H.; Hsu, M.T.; et al. Cisd2 deficiency drives premature aging and causes mitochondria-mediated defects in mice.
177. Shen, Z.Q.; Chen, Y.F.; Chen, J.R.; Jou, Y.S.; Wu, P.C.; Kao, C.H.; Wang, C.H.; Huang, Y.L.; Chen, C.F.; Huang, T.S.; et al. CISD2 Haploinsufficiency Disrupts Calcium Homeostasis, Causes Nonalcoholic Fatty Liver Disease, and Promotes Hepatocellular Carcinoma. *Cell Rep* 2017, 21, 2198–2211. https://doi.org/10.1016/j.celrep.2017.10.099.

178. Danielpur, L.; Sohn, Y.S.; Karmi, O.; Fogel, C.; Zinger, A.; Abu-Libdeh, A.; Israeli, T.; Riahi, Y.; Pappo, O.; Birk, R.; et al. GLP-1 RA Corrects Mitochondrial Labile Iron Accumulation and Improves beta-Cell Function in Type 2 Wolfram Syndrome. *J Clin Endocrinol Metab* 2016, 101, 3592–3599. https://doi.org/10.1210/jc.2016-2240.

179. Holt, S.H.; Darash-Yahana, M.; Sohn, Y.S.; Song, L.; Karmi, O.; Tamir, S.; Michaeli, D.; Luo, Y.; Paddock, M.L.; Jennings, P.A.; et al. Activation of apoptosis in NAF-1-deficient human epithelial breast cancer cells. *J Cell Sci* 2016, 129, 155–165. https://doi.org/10.1242/jcs.178293.

180. Fonseca, S.G.; Ishigaki, S.; Olsowski, C.M.; Lu, S.; Lipson, K.L.; Ghosh, R.; Hayashi, E.; Ishihara, H.; Oka, Y.; Permutt, M.A.; et al. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. *J Clin Invest* 2010, 120, 744–755. https://doi.org/10.1172/JCI39678.

181. Bonnet Wersinger, D.; Benkafadar, N.; Jagodzinska, J.; Hamel, C.; Tanizawa, Y.; Lenera, G.; Delettre, C. Impairment of visual function and retinal ER stress activation in Wfs1-deficient mice. *PLoS One* 2014, 9, e97222. https://doi.org/10.1371/journal.pone.0097222.

182. Win, S.; Than, T.A.; Fernandez-Checa, J.C.; Kaplowitz, N. JNK interaction with Sab mediates ER stress induced inhibition of mitochondrial respiration and cell death. *Cell Death Dis* 2014, 5, e989. https://doi.org/10.1038/cddis.2013.522.

183. Medeiros, R.; Baglietto-Vargas, D.; LaFerla, F.M. The role of tau in Alzheimer’s disease and related disorders. *CNS Neurosci Ther* 2011, 17, 514–524. https://doi.org/10.1111/j.1755-5949.2010.01777.x.

184. Chen, S.; Acosta, D.; Li, L.; Liang, J.; Chang, Y.; Wang, C.; Fitzgerald, J.; Morrison, C.; Goulbourne, C.; Nakano, Y.; et al. Wolfmin is a novel regulator of tau pathology and neurodegeneration. *Acta Neuropathol* 2022, 143, 547–569. https://doi.org/10.1007/s00401-022-02417-4.

185. Oules, B.; Del Prete, D.; Greco, B.; Zhang, X.; Lauritzen, I.; Sevalle, J.; Moreno, S.; Paterlini-Brechot, P.; Trebak, M.; Checker, F.; et al. Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease. *J Neurosci* 2012, 32, 11820–11834. https://doi.org/10.1523/JNEUROSCI.0840-12.2012.

186. Lacampagne, A.; Liu, X.; Reiken, S.; Bussiere, R.; Meli, A.C.; Lauritzen, I.; Teich, A.F.; Zalk, R.; Saint, N.; Arancio, O.; et al. Post-translational remodeling of ryanodine receptor induces calcium leak leading to Alzheimer’s disease-like pathologies and cognitive deficits. *Acta Neuropathologica* 2017, 134, 749–767. https://doi.org/10.1007/s00401-017-1733-7.

187. Yao, J.; Liu, Y.; Sun, B.; Zhan, X.; Estillore, J.P.; Turner, R.W.; Chen, S.W. Increased RyR2 open probability induces neuronal hyperactivity and memory loss with or without Alzheimer’s disease-causing gene mutations. *Alzheimers Dement* 2022. https://doi.org/10.1002/alz.12543.

188. Iwamoto, M.; Nakamura, Y.; Takemura, M.; Hisaoka-Nakashima, K.; Morioka, N. TLR4-TAK1-p38 MAPK pathway and HDAC6 regulate the expression of sigma-1 receptors in rat primary cultured microglia. *J Pharmacol Sci* 2020, 144, 23–29. https://doi.org/10.1016/j.jphs.2020.06.007.

189. Frause, J.; Goswami, A.; Katona, I.; Roos, A.; Schnizler, M.; Bushuven, E.; Dreier, A.; Buchkremer, S.; Johann, S.; Beyer, C.; et al. Altered localization, abnormal modification and loss of function of Sigma receptor-1 in amyotrophic lateral sclerosis. *Hum Mol Genet* 2013, 22, 1581–1600. https://doi.org/10.1093/hmg/ddt008.

190. Mishina, M.; Ishiwata, K.; Ishii, K.; Kitamura, S.; Kimura, Y.; Kawamura, K.; Oda, K.; Sasaki, T.; Sakayori, O.; Hamamoto, M.; et al. Function of sigma1 receptors in Parkinson’s disease. *Acta Neurol Scand* 2005, 112, 103–107. https://doi.org/10.1111/j.1600-0404.2005.00432.x.

191. Ryskamp, D.; Wu, L.; Wu, J.; Kim, D.; Rammes, G.; Geva, M.; Hayden, M.; Bezprozvanny, I. Pridopidine stabilizes mushroom spines in mouse models of Alzheimer’s disease by acting on the sigma-1 receptor. *Neurobiol Dis* 2019, 124, 489–504. https://doi.org/10.1016/j.nbd.2018.12.022.

192. Callens, M.; Kraskovskaya, N.; Derertsova, K.; Annaert, W.; Bultynck, G.; Bezprozvanny, I.; Vervliet, T. The role of Bcl-2 proteins in modulating neuronal Ca²⁺ signaling in health and in Alzheimer’s disease. *Biochim Biophys Acta Mol Cell Res* 2021, 1868, 118997. https://doi.org/10.1016/j.bbamcr.2021.118997.

193. Rohn, T.T.; Vyas, V.; Hernandez-Estrada, T.; Nichol, K.E.; Christie, L.A.; Head, E. Lack of pathology in a triple transgenic mouse model of Alzheimer’s disease after overexpression of the anti-apoptotic protein Bcl-2. *Journal of Neuroscience* 2008, 28, 3051–3059. https://doi.org/10.1523/JNEUROSCI.5620-07.2008.

194. Li, L.; Venkataraman, L.; Chen, S.; Fu, H. Function of WFS1 and WFS2 in the Central Nervous System: Implications for Wolfram Syndrome and Alzheimer’s disease. *Neurosci Biobehav Rev* 2020, 118, 775–783. https://doi.org/10.1016/j.neubiorev.2020.09.011.